Statistical	O
methods	O
We	O
analyzed	O
correlations	O
between	O
categorical	O
variables	O
using	O
the	O
χ2	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

We	O
used	O
analysis	O
of	O
variance	O
to	O
study	O
correlations	O
between	O
continuous	O
and	O
categorical	O
variables	O
,	O
and	O
simple	O
regression	O
to	O
analyze	O
correlations	O
between	O
continuous	O
variables	O
.	O

p53	O
mutation	O
is	O
strongly	O
associated	O
with	O
Type	O
A	O
MSI	O
in	O
human	O
colorectal	O
cancer	O
One	O
view	O
of	O
the	O
involvement	O
of	O
MMR	O
defects	O
in	O
cancer	O
development	O
is	O
that	O
the	O
'	O
microsatellite	O
mutator	O
phenotype	O
(	O
MMP	O
)	O
'	O
(	O
29,30	O
)	O
in	O
mismatch	O
repair	O
-	O
defective	O
cells	O
offers	O
an	O
alternative	O
to	O
chromosomal	O
instability	O
as	O
a	O
mechanism	O
for	O
genetic	O
instability	O
in	O
cancer	O
(	O
31	O
)	O
.	O

On	O
this	O
model	O
,	O
MSI	O
and	O
chromosomal	O
instability	O
represent	O
mutually	O
exclusive	O
pathways	O
of	O
tumour	O
development	O
.	O

This	O
reasoning	O
is	O
based	O
partly	O
in	O
the	O
observation	O
that	O
p53	O
mutations	O
,	O
commonly	O
associated	O
with	O
chromosomal	O
instability	O
,	O
are	O
infrequent	O
among	O
MSI+	O
tumours	O
(	O
2,32–34	O
)	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
Type	O
A	O
/	O
B	O
instability	O
and	O
p53	O
mutation	O
,	O
we	O
sequenced	O
the	O
p53	O
gene	O
in	O
our	O
panel	O
of	O
79	O
colorectal	O
tumours	O
.	O

p53	O
mutations	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
were	O
detected	O
in	O
23	O
tumours	O
(	O
29.1	O
%	O
)	O
.	O

The	O
mutations	O
were	O
predominantly	O
transitions	O
in	O
acknowledged	O
hot	O
spots	O
;	O
codons	O
175	O
,	O
248	O
and	O
273	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
p53	O
mutations	O
that	O
were	O
found	O
in	O
MSI+	O
tumours	O
,	O
all	O
were	O
associated	O
with	O
Type	O
A	O
MSI	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

No	O
p53	O
mutations	O
were	O
detected	O
among	O
the	O
14	O
Type	O
B	O
tumours	O
.	O

Among	O
Type	O
A	O
tumours	O
,	O
the	O
frequency	O
of	O
p53	O
mutation	O
approached	O
50	O
%	O
(	O
12	O
/	O
25	O
)	O
.	O

These	O
findings	O
confirm	O
that	O
p53	O
mutations	O
are	O
rare	O
in	O
tumours	O
with	O
Type	O
B	O
MSI	O
.	O

More	O
importantly	O
,	O
they	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
defective	O
MMR	O
is	O
significantly	O
associated	O
with	O
p53	O
mutation	O
,	O
at	O
least	O
in	O
human	O
colorectal	O
cancer	O
.	O

Discussion	O
The	O
exact	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
.	O

With	O
simple	O
multistage	O
models	O
[	O
3	O
-	O
6,11	O
]	O
,	O
all	O
cancers	O
of	O
a	O
given	O
type	O
require	O
the	O
same	O
number	O
of	O
oncogenic	O
mutations	O
,	O
but	O
stochastic	O
differences	O
in	O
the	O
times	O
to	O
accumulate	O
these	O
mutations	O
allow	O
individual	O
cancers	O
to	O
appear	O
at	O
different	O
ages	O
.	O

Precisely	O
when	O
and	O
how	O
quickly	O
mutations	O
accumulate	O
are	O
unknown	O
,	O
but	O
a	O
basic	O
premise	O
is	O
that	O
cancer	O
types	O
requiring	O
more	O
mutations	O
will	O
tend	O
to	O
appear	O
later	O
in	O
life	O
.	O

Therefore	O
,	O
numbers	O
of	O
mutations	O
may	O
be	O
estimated	O
from	O
cancer	O
epidemiology	O
.	O

Colorectal	O
cancer	O
frequencies	O
increase	O
with	O
age	O
,	O
and	O
the	O
pattern	O
of	O
this	O
increase	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
[	O
3	O
-	O
6	O
]	O
.	O

In	O
this	O
study	O
numbers	O
of	O
mutations	O
were	O
estimated	O
for	O
well	O
-	O
defined	O
subgroups	O
of	O
colorectal	O
cancers	O
because	O
biological	O
heterogeneity	O
may	O
confound	O
this	O
type	O
of	O
quantitative	O
analysis	O
.	O

Such	O
estimates	O
should	O
be	O
considered	O
rough	O
guides	O
rather	O
than	O
absolute	O
values	O
because	O
our	O
model	O
does	O
not	O
account	O
for	O
all	O
factors	O
.	O

Cancers	O
were	O
classified	O
as	O
MSI+	O
or	O
MSI-	O
,	O
and	O
MSI+	O
cancers	O
were	O
further	O
sub	O
-	O
classified	O
as	O
either	O
hereditary	O
(	O
HNPCC	O
)	O
or	O
sporadic	O
.	O

As	O
expected	O
because	O
one	O
MMR	O
mutation	O
is	O
inherited	O
,	O
estimated	O
numbers	O
of	O
critical	O
mutations	O
were	O
less	O
for	O
MSI+	O
HNPCC	O
cancers	O
compared	O
to	O
sporadic	O
MSI+	O
cancers	O
.	O

However	O
,	O
sporadic	O
MSI+	O
cancers	O
required	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
compared	O
to	O
HNPCC	O
cancers	O
.	O

Of	O
interest	O
,	O
a	O
difference	O
of	O
more	O
than	O
a	O
single	O
mutation	O
has	O
also	O
been	O
inferred	O
between	O
sporadic	O
and	O
FAP	O
cancers	O
,	O
with	O
estimates	O
of	O
three	O
to	O
four	O
mutations	O
for	O
FAP	O
cancers	O
versus	O
six	O
for	O
sporadic	O
cancers	O
[	O
6,13	O
]	O
,	O
although	O
another	O
analysis	O
was	O
consistent	O
with	O
a	O
difference	O
of	O
only	O
a	O
single	O
mutation	O
[	O
14	O
]	O
.	O

Therefore	O
,	O
germline	O
mutations	O
(	O
APC	O
and	O
MMR	O
loci	O
)	O
in	O
both	O
common	O
colorectal	O
familial	O
cancer	O
syndromes	O
(	O
FAP	O
and	O
HNPCC	O
)	O
appear	O
to	O
advance	O
progression	O
by	O
more	O
than	O
a	O
single	O
mutation	O
relative	O
to	O
their	O
sporadic	O
counterparts	O
.	O

An	O
epigenetic	O
mechanism	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
require	O
more	O
than	O
one	O
additional	O
somatic	O
alteration	O
relative	O
to	O
HNPCC	O
cancers	O
.	O

Inactivation	O
of	O
the	O
normal	O
MMR	O
allele	O
occurs	O
through	O
mutation	O
(	O
usually	O
LOH	O
[	O
15	O
]	O
)	O
in	O
HNPCC	O
whereas	O
MMR	O
loss	O
in	O
sporadic	O
MSI+	O
cancers	O
is	O
associated	O
with	O
MLH1	O
promoter	O
methylation	O
[	O
16,17	O
]	O
.	O

CpG	O
islands	O
may	O
be	O
""""	O
protected	O
""""	O
from	O
methylation	O
because	O
most	O
are	O
unmethylated	O
at	O
birth	O
and	O
usually	O
remain	O
unmethylated	O
throughout	O
life	O
[	O
18	O
]	O
.	O

Epigenetic	O
MLH1	O
inactivation	O
may	O
require	O
at	O
least	O
two	O
cis	O
acting	O
somatic	O
alterations	O
---	O
loss	O
of	O
a	O
mechanism	O
that	O
normally	O
prevents	O
methylation	O
,	O
followed	O
by	O
the	O
accumulation	O
of	O
methylation	O
at	O
sufficient	O
numbers	O
of	O
CpG	O
sites	O
to	O
silence	O
expression	O
.	O

In	O
agreement	O
with	O
prior	O
studies	O
,	O
there	O
were	O
seven	O
mutations	O
estimated	O
for	O
sporadic	O
MSI-	O
Finnish	O
cancers	O
[	O
4	O
]	O
,	O
and	O
seven	O
or	O
eight	O
mutations	O
for	O
MSI+	O
cancers	O
.	O

A	O
requirement	O
for	O
more	O
alterations	O
before	O
tranformation	O
for	O
sporadic	O
MSI+	O
compared	O
to	O
sporadic	O
MSI-	O
cancers	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
are	O
a	O
minority	O
of	O
all	O
colorectal	O
cancers	O
and	O
occur	O
in	O
slightly	O
older	O
patients	O
[	O
19,20	O
]	O
.	O

Although	O
numbers	O
of	O
oncogenic	O
mutations	O
before	O
transformation	O
are	O
similar	O
between	O
sporadic	O
MSI+	O
and	O
MSI-	O
cancers	O
,	O
their	O
identities	O
likely	O
differ	O
[	O
7,8	O
]	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
the	O
occurrence	O
of	O
mutations	O
in	O
the	O
APC	O
,	O
CTNNB1	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
expression	O
of	O
the	O
hMLH1	O
protein	O
in	O
tumour	O
tissue	O
of	O
656	O
sporadic	O
colorectal	O
cancer	O
cases	O
were	O
investigated	O
.	O

The	O
occurrence	O
of	O
mutations	O
in	O
the	O
CTNNB1	O
gene	O
,	O
which	O
codes	O
for	O
β	O
-	O
catenin	O
,	O
was	O
rare	O
:	O
only	O
five	O
of	O
464	O
tumours	O
analysed	O
were	O
found	O
to	O
have	O
a	O
mutation	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
.	O

Truncating	O
mutations	O
in	O
APC	O
and	O
activating	O
mutations	O
in	O
K	O
-	O
ras	O
appeared	O
to	O
occur	O
at	O
similar	O
frequencies	O
.	O

Although	O
tumours	O
harbouring	O
both	O
mutations	O
were	O
relatively	O
rare	O
,	O
mutations	O
in	O
APC	O
and	O
K	O
-	O
ras	O
seemed	O
to	O
occur	O
co	O
-	O
dependently	O
.	O

Nine	O
percent	O
of	O
all	O
tumours	O
(	O
58	O
/	O
656	O
)	O
lacked	O
hMLH1	O
expression	O
,	O
and	O
in	O
these	O
tumours	O
almost	O
no	O
APC	O
or	O
K	O
-	O
ras	O
mutations	O
was	O
detected	O
.	O

Patients	O
harbouring	O
a	O
tumour	O
with	O
absent	O
hMLH1	O
expression	O
were	O
older	O
,	O
more	O
often	O
women	O
,	O
more	O
often	O
had	O
proximal	O
colon	O
tumours	O
that	O
showed	O
poorer	O
differentiation	O
when	O
compared	O
to	O
patients	O
who	O
harboured	O
a	O
tumour	O
with	O
an	O
APC	O
and/or	O
K	O
-	O
ras	O
mutation	O
.	O

The	O
selection	O
of	O
patients	O
included	O
in	O
this	O
study	O
was	O
based	O
on	O
the	O
completeness	O
of	O
analyses	O
of	O
both	O
APC	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
hMLH1	O
expression	O
and	O
this	O
led	O
to	O
a	O
considerable	O
reduction	O
in	O
the	O
number	O
of	O
cases	O
that	O
could	O
be	O
included	O
in	O
the	O
analyses	O
presented	O
in	O
this	O
study	O
.	O

The	O
largest	O
reduction	O
(	O
72	O
cases	O
)	O
was	O
due	O
to	O
incompleteness	O
of	O
the	O
analysis	O
of	O
all	O
fragments	O
comprising	O
the	O
APC	O
mutation	O
cluster	O
region	O
.	O

Tumour	O
DNA	O
was	O
derived	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumour	O
tissue	O
blocks	O
.	O

Depending	O
on	O
the	O
conditions	O
of	O
fixation	O
and	O
storage	O
,	O
the	O
extracted	O
DNA	O
is	O
more	O
or	O
less	O
fragmented	O
,	O
which	O
may	O
have	O
impaired	O
the	O
analysis	O
of	O
mutations	O
in	O
the	O
APC	O
gene	O
more	O
than	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
since	O
the	O
analysis	O
of	O
the	O
latter	O
is	O
based	O
on	O
the	O
amplification	O
of	O
a	O
smaller	O
gene	O
fragment	O
.	O

It	O
should	O
be	O
emphasized	O
that	O
characteristics	O
of	O
patients	O
(	O
age	O
,	O
sex	O
,	O
family	O
history	O
of	O
colorectal	O
cancer	O
)	O
and	O
tumours	O
(	O
sub	O
-	O
localisation	O
,	O
Dukes	O
'	O
stage	O
and	O
differentiation	O
)	O
of	O
the	O
group	O
under	O
study	O
are	O
similar	O
to	O
the	O
737	O
patients	O
for	O
whom	O
tumour	O
material	O
was	O
available	O
and	O
to	O
all	O
819	O
patients	O
initially	O
recognized	O
within	O
the	O
cohort	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
the	O
K	O
-	O
ras	O
and	O
hMLH1data	O
presented	O
here	O
are	O
similar	O
to	O
the	O
data	O
for	O
K	O
-	O
ras	O
and	O
hMLH1	O
based	O
on	O
the	O
complete	O
groups	O
(	O
737	O
and	O
724	O
cases	O
,	O
respectively	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutations	O
in	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
leading	O
to	O
loss	O
of	O
one	O
of	O
the	O
phosphorylation	O
sites	O
were	O
rare	O
.	O

Strikingly	O
,	O
all	O
five	O
of	O
these	O
mutations	O
occurred	O
in	O
the	O
proximal	O
colon	O
and	O
three	O
of	O
these	O
also	O
had	O
absent	O
hMLH1	O
expression	O
.	O

This	O
may	O
indicate	O
that	O
these	O
proximal	O
colon	O
tumours	O
,	O
which	O
often	O
also	O
show	O
mismatch	O
repair	O
deficiency	O
,	O
are	O
more	O
likely	O
to	O
harbour	O
CTNNB1	O
mutations	O
.	O

This	O
was	O
also	O
found	O
in	O
a	O
study	O
of	O
microsatellite	O
instable	O
colorectal	O
tumours	O
[	O
26	O
]	O
.	O

The	O
WAVE	O
screening	O
technique	O
has	O
not	O
been	O
used	O
previously	O
for	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
and	O
therefore	O
it	O
seems	O
plausible	O
that	O
samples	O
harbouring	O
a	O
CTNNB1	O
mutation	O
have	O
escaped	O
detection	O
.	O

However	O
,	O
all	O
58	O
hMLH1	O
deficient	O
samples	O
were	O
analysed	O
by	O
direct	O
sequencing	O
without	O
a	O
prior	O
screening	O
step	O
,	O
and	O
only	O
three	O
of	O
these	O
samples	O
harboured	O
a	O
CTNNB1	O
mutation	O
,	O
indicating	O
the	O
low	O
frequency	O
of	O
such	O
mutations	O
.	O

Background	O
Hereditary	O
non	O
-	O
polyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
is	O
an	O
inherited	O
syndrome	O
predisposing	O
to	O
the	O
early	O
development	O
of	O
cancers	O
of	O
colon	O
,	O
rectum	O
,	O
endometrium	O
,	O
ovarium	O
,	O
small	O
bowel	O
,	O
stomach	O
and	O
urinary	O
tract	O
[	O
1,2	O
]	O
.	O

Since	O
there	O
are	O
no	O
premonitory	O
signs	O
of	O
susceptibility	O
to	O
HNPCC	O
,	O
family	O
history	O
has	O
been	O
the	O
primary	O
method	O
for	O
identifying	O
patients	O
at	O
risk	O
.	O

Defined	O
by	O
the	O
International	O
Collaborative	O
group	O
on	O
HNPCC	O
,	O
the	O
typical	O
HNPCC	O
family	O
fulfill	O
the	O
following	O
criteria	O
(	O
referred	O
to	O
as	O
the	O
Amsterdam	O
-	O
I	O
criteria	O
[	O
3	O
]	O
)	O
:	O
1	O
.	O

Three	O
or	O
more	O
relatives	O
with	O
histologically	O
verified	O
colorectal	O
cancer	O
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
.	O

Colorectal	O
cancer	O
affecting	O
at	O
least	O
2	O
successive	O
generations	O
;	O
and	O
3	O
.	O

At	O
least	O
one	O
relative	O
diagnosed	O
with	O
colorectal	O
cancer	O
under	O
the	O
age	O
of	O
50	O
.	O

The	O
fulfillment	O
of	O
these	O
criteria	O
prompted	O
further	O
genetics	O
investigations	O
.	O

More	O
recently	O
it	O
has	O
been	O
revised	O
to	O
take	O
into	O
account	O
the	O
prevalence	O
of	O
extracolonic	O
cancer	O
in	O
certain	O
HNPCC	O
families	O
[	O
4	O
]	O
.	O

This	O
autosomal	O
dominantly	O
inherited	O
disorder	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
genes	O
coding	O
proteins	O
responsible	O
for	O
the	O
repair	O
of	O
DNA	O
replication	O
errors	O
,	O
which	O
are	O
referred	O
to	O
as	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
[	O
5	O
]	O
.	O

DNA	O
mismatch	O
repair	O
machinery	O
plays	O
a	O
critical	O
role	O
in	O
genomic	O
stability	O
,	O
including	O
correction	O
of	O
mispaired	O
bases	O
associated	O
with	O
DNA	O
replication	O
and	O
recombination	O
.	O

Germline	O
mutations	O
in	O
one	O
allele	O
of	O
any	O
of	O
these	O
genes	O
followed	O
by	O
the	O
somatic	O
loss	O
or	O
inactivation	O
of	O
the	O
wild	O
-	O
type	O
allele	O
leads	O
to	O
a	O
defective	O
mismatch	O
repair	O
mechanism	O
.	O

The	O
current	O
""""	O
gold	O
standard	O
""""	O
for	O
assessing	O
tumor	O
DNA	O
MMR	O
activity	O
is	O
molecular	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
testing	O
.	O

In	O
most	O
cases	O
,	O
it	O
involves	O
extracting	O
DNA	O
from	O
both	O
tumor	O
and	O
normal	O
tissue	O
.	O

The	O
DNA	O
is	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
five	O
or	O
more	O
different	O
chromosomal	O
loci	O
that	O
compare	O
""""	O
microsatellites	O
""""	O
,	O
running	O
the	O
PCR	O
products	O
through	O
a	O
gel	O
to	O
separate	O
DNA	O
fragments	O
by	O
size	O
,	O
comparing	O
the	O
tumor	O
-	O
normal	O
pairs	O
,	O
and	O
scoring	O
for	O
differences	O
between	O
the	O
two	O
.	O

Instability	O
at	O
two	O
or	O
more	O
out	O
of	O
five	O
markers	O
defines	O
a	O
tumor	O
as	O
MSI	O
-	O
H	O
and	O
prompts	O
further	O
analysis	O
,	O
as	O
sequencing	O
of	O
DNA	O
MMR	O
genes	O
.	O

A	O
number	O
of	O
them	O
have	O
been	O
associated	O
with	O
HNPCC	O
,	O
including	O
hMSH2	O
,	O
hMLH1	O
,	O
hPMS1	O
,	O
hPMS2	O
,	O
hMSH3	O
,	O
and	O
hMSH6	O
.	O

Most	O
of	O
the	O
HNPCC	O
families	O
in	O
which	O
mutations	O
have	O
been	O
identified	O
involved	O
hMSH2	O
and	O
hMLH1	O
genes	O
[	O
6	O
]	O
.	O

A	O
much	O
less	O
labor	O
-	O
intensive	O
alternative	O
method	O
used	O
to	O
prescreen	O
high	O
-	O
risk	O
individuals	O
for	O
further	O
germline	O
mutation	O
analysis	O
is	O
immunohistochemistry	O
(	O
IHC	O
)	O
testing	O
for	O
MLH1	O
and	O
MSH2	O
expression	O
.	O

IHC	O
testing	O
may	O
identify	O
which	O
gene	O
to	O
target	O
for	O
analysis	O
.	O

We	O
describe	O
MSI	O
testing	O
in	O
the	O
absence	O
of	O
proband	O
non	O
-	O
tumor	O
tissue	O
using	O
the	O
Bethesda	O
consensus	O
panel	O
(	O
mononucleotide	O
repeats	O
BAT25	O
and	O
BAT26	O
,	O
and	O
dinucleotide	O
repeats	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
and	O
we	O
report	O
a	O
novel	O
hMSH2	O
germline	O
mutation	O
found	O
in	O
the	O
family	O
.	O

Microsatellite	O
instability	O
.	O

Three	O
of	O
five	O
microsatellite	O
markers	O
(	O
BAT-25	O
,	O
BAT-26	O
and	O
D5S346	O
)	O
presented	O
different	O
alleles	O
(	O
*	O
)	O
in	O
the	O
proband	O
's	O
primary	O
tumor	O
(	O
T	O
'	O
)	O
and	O
its	O
metastasis	O
(	O
T	O
""""	O
)	O
of	O
those	O
inherited	O
from	O
his	O
biological	O
mother	O
(	O
BM	O
)	O
and	O
father	O
(	O
BF	O
)	O
.	O

DNA	O
sequencing	O
of	O
hMSH2	O
and	O
hMLH1	O
genes	O
A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
the	O
proband	O
's	O
mother	O
and	O
forwarded	O
to	O
the	O
Department	O
of	O
Clinical	O
Cancer	O
Genetics	O
(	O
City	O
of	O
Hope	O
Cancer	O
Center	O
,	O
Duarte	O
,	O
California	O
,	O
USA	O
)	O
to	O
full	O
mutation	O
analysis	O
of	O
the	O
hMSH2	O
and	O
hMLH1	O
genes	O
.	O

The	O
sample	O
was	O
amplified	O
followed	O
by	O
direct	O
sequencing	O
to	O
screen	O
the	O
coding	O
regions	O
of	O
both	O
the	O
hMSH2	O
and	O
the	O
hMLH1	O
genes	O
for	O
germline	O
mutation	O
in	O
the	O
DNA	O
.	O

After	O
establishing	O
the	O
familial	O
mutation	O
in	O
the	O
proband	O
's	O
mother	O
,	O
located	O
in	O
the	O
exon	O
12	O
of	O
hMSH2	O
gene	O
,	O
it	O
was	O
searched	O
in	O
the	O
proband	O
's	O
sisters	O
by	O
direct	O
sequencing	O
using	O
a	O
manual	O
Sequenase	O
PCR	O
products	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Mutation	O
screening	O
was	O
done	O
in	O
both	O
sisters	O
to	O
assign	O
their	O
risk	O
to	O
develop	O
HNPCC	O
and	O
other	O
related	O
cancers	O
.	O

We	O
found	O
the	O
mutation	O
in	O
one	O
of	O
them	O
and	O
opportune	O
recommendations	O
for	O
surveillance	O
and	O
prophylaxis	O
were	O
given	O
.	O

Two	O
years	O
after	O
that	O
,	O
the	O
proband	O
's	O
mother	O
,	O
unaffected	O
during	O
this	O
study	O
,	O
developed	O
an	O
endometrial	O
adenocarcinoma	O
.	O

Methods	O
Patients	O
25	O
colorectal	O
cancer	O
patients	O
undergoing	O
elective	O
standard	O
oncological	O
resection	O
at	O
the	O
department	O
of	O
surgery	O
,	O
Charité	O
,	O
Campus	O
Benjamin	O
Franklin	O
,	O
Berlin	O
,	O
Germany	O
were	O
prospectively	O
recruited	O
for	O
this	O
study	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethical	O
committee	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O

Rectal	O
cancer	O
patients	O
receiving	O
neo	O
-	O
adjuvant	O
radiochemotherapy	O
were	O
excluded	O
from	O
this	O
study	O
.	O

Tissue	O
samples	O
and	O
UV	O
-	O
laser	O
microdissection	O
Transmural	O
cancer	O
specimens	O
were	O
snap	O
frozen	O
(	O
liquid	O
nitrogen	O
)	O
within	O
20	O
minutes	O
following	O
excision	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

All	O
tissue	O
samples	O
were	O
evaluated	O
by	O
a	O
pathologist	O
before	O
and	O
during	O
laser	O
micro	O
-	O
dissection	O
to	O
ensure	O
an	O
enrichment	O
of	O
vital	O
tumor	O
cells	O
.	O

Six	O
-	O
micron	O
serial	O
frozen	O
sections	O
were	O
cut	O
on	O
a	O
standard	O
cryostat	O
and	O
mounted	O
on	O
RNase	O
-	O
free	O
foil	O
(	O
2,5	O
μm	O
)	O
coated	O
on	O
glass	O
slides	O
followed	O
by	O
immediate	O
fixation	O
(	O
70	O
%	O
ethanol	O
for	O
30s	O
)	O
,	O
H&E	O
staining	O
,	O
and	O
ethanol	O
dehydration	O
(	O
70	O
%	O
,	O
95	O
%	O
and	O
finally	O
100	O
%	O
ethanol	O
)	O
.	O

After	O
vacuum	O
drying	O
the	O
membranes	O
carrying	O
the	O
sections	O
were	O
manually	O
turned	O
and	O
coated	O
on	O
new	O
RNase	O
free	O
glass	O
slides	O
.	O

Optically	O
transparent	O
CapSure	O
LCM	O
caps	O
(	O
ARCTURUS	O
,	O
CA	O
)	O
were	O
placed	O
on	O
the	O
foil	O
over	O
a	O
selected	O
field	O
of	O
cells	O
.	O

Vital	O
colorectal	O
epithelial	O
carcinoma	O
cells	O
(	O
>	O
90	O
%	O
proportion	O
)	O
from	O
the	O
invasion	O
front	O
were	O
isolated	O
using	O
UV	O
-	O
LCM	O
Systems	O
from	O
PALM	O
(	O
Microlaser	O
Technologie	O
,	O
Germany	O
)	O
and	O
SL	O
(	O
Microtest	O
GmbH	O
,	O
Germany	O
)	O
.	O

After	O
visual	O
control	O
of	O
completeness	O
of	O
dissection	O
the	O
captured	O
cells	O
were	O
immersed	O
in	O
denaturation	O
buffer	O
(	O
GTC	O
Extraction	O
Buffer	O
,	O
2	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
Promega	O
,	O
WI	O
)	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

mRNA	O
-	O
extraction	O
,	O
cRNA	O
-	O
preparation	O
and	O
-amplification	O
Poly	O
(	O
A	O
)	O
+	O
RNAs	O
were	O
isolated	O
using	O
PolyATtract	O
1000	O
kit	O
(	O
Promega	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

For	O
each	O
sample	O
the	O
cDNA	O
synthesis	O
and	O
repetitive	O
in	O
vitro	O
transcription	O
were	O
performed	O
three	O
times	O
,	O
as	O
described	O
previously	O
[	O
38	O
-	O
40	O
]	O
.	O

In	O
brief	O
,	O
the	O
total	O
amount	O
of	O
prepared	O
mRNA	O
from	O
one	O
sample	O
was	O
used	O
.	O

First	O
strand	O
cDNA	O
synthesis	O
was	O
initiated	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
.	O

The	O
second	O
strand	O
cDNA	O
was	O
synthesized	O
by	O
internal	O
priming	O
.	O

In	O
vitro	O
transcription	O
was	O
performed	O
using	O
Ambion	O
's	O
Megascript	O
kit	O
(	O
Ambion	O
,	O
Huntington	O
,	O
UK	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

From	O
the	O
generated	O
cRNA	O
a	O
new	O
first	O
strand	O
synthesis	O
was	O
initiated	O
using	O
0.025	O
mM	O
of	O
a	O
random	O
hexamer	O
as	O
primer	O
.	O

After	O
completion	O
,	O
the	O
second	O
strand	O
synthesis	O
was	O
primed	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
at	O
a	O
concentration	O
of	O
0.1	O
mM.	O
A	O
second	O
in	O
vitro	O
transcription	O
was	O
performed	O
and	O
then	O
the	O
procedure	O
was	O
repeated	O
one	O
additional	O
time	O
.	O

During	O
the	O
third	O
in	O
vitro	O
transcription	O
biotin	O
-	O
labeled	O
nucleotides	O
were	O
incorporated	O
into	O
the	O
cRNA	O
as	O
recommended	O
by	O
the	O
Affymetrix	O
protocol	O
.	O

Microarray	O
hybridization	O
BIO+cRNAs	O
were	O
hybridized	O
on	O
Affymetrix	O
Human	O
Genome	O
U133A	O
and	O
U133B	O
GeneChips	O
,	O
that	O
consist	O
of	O
44.928	O
probe	O
sets	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Fragmentation	O
,	O
preparation	O
of	O
hybridization	O
cocktails	O
,	O
hybridization	O
,	O
washing	O
,	O
staining	O
and	O
scanning	O
of	O
Affymetrix	O
GeneChip	O
were	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocols	O
.	O

Introduction	O

The	O
traditional	O
view	O
of	O
epithelial	O
polyps	O
of	O
the	O
colorectum	O
envisages	O
a	O
larger	O
non	O
-	O
neoplastic	O
category	O
of	O
hyperplastic	O
polyps	O
(	O
HPs	O
)	O
that	O
can	O
be	O
safely	O
ignored	O
and	O
a	O
smaller	O
category	O
of	O
neoplastic	O
polyps	O
or	O
adenomas	O
that	O
are	O
precancerous.1	O
With	O
respect	O
to	O
adenomas	O
,	O
it	O
is	O
clear	O
that	O
the	O
majority	O
will	O
not	O
progress	O
to	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.2	O
The	O
risk	O
of	O
cancer	O
developing	O
within	O
an	O
adenoma	O
increases	O
with	O
size	O
,	O
grade	O
of	O
dysplasia	O
(	O
synonymous	O
with	O
intraepithelial	O
neoplasia	O
)	O
and	O
villosity.3	O
These	O
features	O
,	O
together	O
with	O
polyp	O
numbers	O
,	O
are	O
also	O
predictive	O
of	O
metachronous	O
neoplasia	O
and	O
may	O
therefore	O
influence	O
the	O
decision	O
to	O
offer	O
follow	O
-	O
up	O
endoscopic	O
surveillance.4	O
However	O
,	O
the	O
grading	O
of	O
dysplasia	O
and	O
estimation	O
of	O
the	O
extent	O
of	O
villous	O
change	O
may	O
not	O
be	O
fully	O
reproducible	O
and	O
it	O
may	O
be	O
difficult	O
to	O
distinguish	O
new	O
from	O
recurrent	O
adenomas	O
.	O

Establishing	O
a	O
risk	O
profile	O
on	O
the	O
basis	O
of	O
the	O
traditional	O
features	O
of	O
adenoma	O
is	O
therefore	O
not	O
always	O
straightforward	O
.	O

The	O
addition	O
of	O
molecular	O
profiling	O
to	O
polyp	O
description	O
offers	O
hope	O
of	O
a	O
more	O
objective	O
and	O
therefore	O
reproducible	O
approach	O
to	O
the	O
classification	O
of	O
colorectal	O
adenomas	O
.	O

The	O
genetic	O
evolutionary	O
paradigm	O
envisages	O
a	O
linear	O
sequence	O
of	O
changes	O
beginning	O
with	O
bi	O
-	O
allelic	O
inactivation	O
of	O
APC	O
,	O
followed	O
by	O
oncogenic	O
KRAS	O
mutation	O
and	O
culminating	O
in	O
inactivation	O
of	O
TP53	O
at	O
the	O
transition	O
from	O
adenoma	O
to	O
carcinoma.5	O
While	O
there	O
is	O
good	O
evidence	O
that	O
KRAS	O
mutation	O
is	O
associated	O
with	O
advanced	O
adenoma	O
features6	O
and	O
could	O
therefore	O
be	O
used	O
as	O
objective	O
evidence	O
of	O
aggression	O
,	O
this	O
approach	O
has	O
a	O
number	O
of	O
limitations	O
.	O

First	O
,	O
KRAS	O
mutation	O
also	O
occurs	O
frequently	O
in	O
dysplastic	O
aberrant	O
crypt	O
foci	O
(	O
microadenomas	O
)	O
and	O
in	O
some	O
small	O
tubular	O
adenomas	O
,	O
suggesting	O
that	O
KRAS	O
mutation	O
may	O
initiate	O
a	O
subset	O
of	O
small	O
adenomas	O
with	O
limited	O
potential	O
for	O
progression.6,7	O
Second	O
,	O
around	O
70	O
%	O
of	O
CRCs	O
lack	O
mutation	O
of	O
KRAS.8	O
From	O
this	O
it	O
follows	O
that	O
most	O
of	O
the	O
precancerous	O
lesions	O
that	O
eventually	O
become	O
cancers	O
do	O
not	O
in	O
fact	O
have	O
KRAS	O
mutation	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
CRC	O
evolves	O
through	O
a	O
number	O
of	O
pathways	O
and	O
the	O
traditional	O
adenoma	O
–	O
carcinoma	O
sequence	O
,	O
with	O
its	O
accompanying	O
genetic	O
steps	O
,	O
provides	O
a	O
surprisingly	O
narrow	O
window	O
of	O
understanding	O
of	O
this	O
multipathway	O
reality.9	O
In	O
recent	O
years	O
,	O
the	O
fundamental	O
division	O
of	O
colorectal	O
polyps	O
into	O
precancerous	O
adenomas	O
and	O
innocent	O
HPs	O
has	O
begun	O
to	O
erode	O
and	O
the	O
concept	O
of	O
an	O
alternative	O
serrated	O
pathway	O
has	O
gained	O
support	O
.	O

This	O
revision	O
began	O
with	O
the	O
description	O
of	O
an	O
intermediate	O
lesion	O
described	O
as	O
serrated	O
adenoma	O
(	O
SA	O
)	O
.10	O
Initially	O
,	O
however	O
,	O
SA	O
was	O
not	O
conceived	O
as	O
an	O
intermediate	O
category	O
of	O
polyp	O
but	O
essentially	O
as	O
an	O
adenoma	O
with	O
a	O
superimposed	O
serrated	O
architecture	O
that	O
conferred	O
only	O
a	O
superficial	O
likeness	O
to	O
a	O
HP.10	O
Additionally	O
,	O
the	O
mixed	O
polyp	O
(	O
MP	O
)	O
was	O
perceived	O
as	O
a	O
chance	O
collision	O
between	O
a	O
HP	O
and	O
an	O
adenoma	O
,	O
giving	O
a	O
combined	O
polyp	O
.	O

These	O
preliminary	O
interpretations	O
did	O
not	O
represent	O
a	O
major	O
departure	O
from	O
the	O
traditional	O
classification	O
of	O
colorectal	O
polyps	O
but	O
preserved	O
the	O
fundamental	O
distinction	O
of	O
neoplastic	O
adenomas	O
versus	O
non	O
-	O
neoplastic	O
HPs	O
.	O

Statistics	O
Data	O
were	O
analysed	O
by	O
χ2	O
test	O
,	O
Fisher	O
's	O
exact	O
test	O
or	O
T	O
-	O
test	O
,	O
as	O
appropriate	O
,	O
using	O
SAS	O
software	O
,	O
version	O
8.2	O
(	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

P	O
-	O
values	O
<	O
0.05	O
were	O
interpreted	O
as	O
significant	O
.	O

Results	O
KRAS	O
and	O
BRAF	O
mutation	O
DNA	O
failed	O
to	O
amplify	O
in	O
the	O
KRAS	O
assay	O
for	O
one	O
SSA	O
and	O
one	O
TA	O
<	O
10	O
mm	O
.	O

Overall	O
,	O
34	O
of	O
188	O
polyps	O
(	O
18	O
%	O
)	O
had	O
mutation	O
of	O
KRAS	O
.	O

Twenty	O
-	O
eight	O
mutations	O
were	O
in	O
codon	O
12	O
(	O
20	O
G→A	O
,	O
seven	O
G→T	O
and	O
one	O
G→C	O
)	O
and	O
six	O
mutations	O
were	O
in	O
codon	O
13	O
(	O
all	O
G→A	O
)	O
.	O

One	O
serrated	O
adenoma	O
had	O
two	O
KRAS	O
mutations	O
in	O
codon	O
12	O
(	O
G→T	O
at	O
position	O
35	O
and	O
T→G	O
at	O
position	O
36	O
)	O
.	O

BRAF	O
mutation	O
at	O
V600E	O
could	O
be	O
assessed	O
in	O
all	O
polyps	O
except	O
for	O
a	O
single	O
TA	O
<	O
10	O
mm	O
.	O

BRAF	O
mutation	O
was	O
found	O
in	O
82	O
of	O
189	O
polyps	O
(	O
43	O
%	O
)	O
.	O

BRAF	O
and	O
KRAS	O
mutations	O
were	O
negatively	O
correlated	O
,	O
with	O
only	O
four	O
polyps	O
having	O
both	O
mutations	O
(	O
two	O
TAs	O
,	O
one	O
TVA	O
and	O
one	O
SSA	O
)	O
.	O

The	O
three	O
conventional	O
adenomas	O
with	O
mutations	O
of	O
both	O
BRAF	O
and	O
KRAS	O
were	O
among	O
only	O
four	O
adenomas	O
that	O
had	O
any	O
BRAF	O
mutations	O
at	O
all	O
.	O

Mutation	O
frequencies	O
for	O
both	O
KRAS	O
and	O
BRAF	O
were	O
distributed	O
differently	O
across	O
the	O
seven	O
polyp	O
groups	O
(	O
Table	O
1	O
)	O
.	O

Frequency	O
of	O
KRAS	O
and	O
BRAF	O
mutation	O
and	O
loss	O
of	O
expression	O
of	O
O-6-methylguanine	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
by	O
polyp	O
type	O
Mutation	O
frequencies	O
for	O
both	O
KRAS	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
BRAF	O
(	O
P	O
<	O
0.0001	O
)	O
are	O
distributed	O
differently	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
see	O
Results	O
for	O
individual	O
comparisons	O
)	O
.	O

Distribution	O
of	O
MGMT	O
loss	O
differs	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Note	O
:	O
no	O
result	O
for	O
KRAS	O
in	O
one	O
sessile	O
serrated	O
adenoma	O
(	O
SSA	O
)	O
and	O
one	O
tubular	O
adenoma	O
(	O
TA	O
)	O
or	O
for	O
BRAF	O
in	O
one	O
TA	O
.	O

MGMT	O
immunstaining	O
not	O
performed	O
in	O
15	O
polyps	O
(	O
seven	O
HPs	O
,	O
one	O
SSA	O
,	O
one	O
MP	O
and	O
six	O
TAs	O
)	O
.	O

KRAS	O
mutation	O
occurred	O
in	O
26.5	O
%	O
and	O
BRAF	O
mutation	O
in	O
4.8	O
%	O
of	O
adenomas	O
(	O
all	O
types	O
)	O
(	O
Table	O
1	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

TVAs	O
/	O
VAs	O
were	O
more	O
likely	O
to	O
have	O
KRAS	O
mutation	O
(	O
50	O
%	O
)	O
than	O
TAs	O
<	O
10	O
mm	O
(	O
18	O
%	O
)	O
(	O
P	O
<	O
0.004	O
)	O
or	O
TAS	O
>	O
10	O
mm	O
in	O
diameter	O
(	O
17	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

In	O
the	O
case	O
of	O
TAs	O
there	O
was	O
a	O
trend	O
for	O
KRAS	O
mutation	O
to	O
occur	O
more	O
frequently	O
in	O
polyps	O
from	O
the	O
proximal	O
colon	O
(	O
P	O
=	O
0.08	O
)	O
and	O
in	O
females	O
(	O
P	O
=	O
0.07	O
)	O
.	O

SSAs	O
were	O
more	O
likely	O
to	O
have	O
BRAF	O
mutation	O
(	O
81	O
%	O
)	O
than	O
either	O
SAs	O
(	O
33	O
%	O
)	O
(	O
P	O
<	O
0.001	O
)	O
or	O
MPs	O
(	O
40	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

KRAS	O
mutation	O
was	O
infrequent	O
among	O
both	O
SSAs	O
(	O
3	O
%	O
)	O
and	O
HPs	O
(	O
4	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O

Patient	O
age	O
,	O
gender	O
and	O
anatomical	O
location	O
were	O
not	O
predictors	O
of	O
BRAF	O
mutation	O
in	O
either	O
SSAs	O
or	O
HPs	O
.	O

The	O
mean	O
age	O
of	O
subjects	O
with	O
SSAs	O
(	O
64	O
years	O
)	O
differed	O
from	O
that	O
of	O
subjects	O
with	O
HPs	O
(	O
55	O
years	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Background	O
Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
in	O
the	O
Western	O
world	O
.	O

Already	O
in	O
1913	O
,	O
familial	O
aggregation	O
of	O
CRC	O
was	O
described	O
by	O
Warthin	O
[	O
1	O
]	O
and	O
later	O
Lynch	O
et	O
al.	O
described	O
an	O
additional	O
family	O
with	O
clustering	O
of	O
colorectal	O
and	O
endometrial	O
cancer	O
[	O
2	O
]	O
.	O

Clinical	O
definition	O
of	O
Lynch	O
syndrome	O
,	O
or	O
HNPCC	O
,	O
in	O
1991	O
[	O
3,4	O
]	O
was	O
instrumental	O
for	O
linkage	O
analysis	O
,	O
and	O
ultimately	O
for	O
the	O
identification	O
of	O
the	O
underlying	O
gene	O
defects	O
in	O
HNPCC	O
families	O
.	O

The	O
first	O
HNPCC	O
loci	O
were	O
mapped	O
to	O
chromosomes	O
2	O
and	O
3	O
using	O
microsatellite	O
markers	O
[	O
5,6	O
]	O
.	O

This	O
eventually	O
led	O
to	O
the	O
identification	O
of	O
germ	O
line	O
mutations	O
in	O
MSH2	O
[	O
7	O
]	O
and	O
MLH1	O
[	O
8	O
]	O
,	O
respectively	O
.	O

Later	O
,	O
PMS2	O
[	O
9	O
]	O
,	O
MSH6	O
[	O
10,11	O
]	O
and	O
recently	O
MutYH	O
[	O
12	O
]	O
were	O
identified	O
as	O
CRC	O
susceptibility	O
genes	O
.	O

However	O
,	O
the	O
so	O
far	O
identified	O
CRC	O
susceptibility	O
genes	O
can	O
only	O
explain	O
up	O
to	O
5	O
%	O
of	O
all	O
cases	O
[	O
13	O
]	O
,	O
while	O
in	O
~35	O
%	O
of	O
all	O
colorectal	O
cancer	O
cases	O
familial	O
clustering	O
is	O
seen	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
that	O
first	O
degree	O
relatives	O
of	O
patients	O
with	O
colorectal	O
cancer	O
have	O
a	O
relative	O
risk	O
of	O
2.3	O
to	O
develop	O
the	O
disease	O
[	O
15	O
]	O
.	O

This	O
indicates	O
that	O
still	O
some	O
genes	O
with	O
strong	O
or	O
moderate	O
effect	O
on	O
CRC	O
development	O
remain	O
to	O
be	O
identified	O
.	O

In	O
order	O
to	O
identify	O
these	O
genes	O
,	O
linkage	O
analysis	O
in	O
families	O
could	O
point	O
to	O
the	O
loci	O
where	O
unknown	O
susceptibility	O
genes	O
may	O
reside	O
.	O

Indeed	O
,	O
different	O
linkage	O
analysis	O
studies	O
revealed	O
potentially	O
interesting	O
regions	O
on	O
chromosomes	O
3q	O
,	O
9q	O
,	O
11q	O
,	O
14q	O
,	O
15q	O
and	O
22q	O
[	O
16	O
-	O
20	O
]	O
.	O

Families	O
with	O
a	O
clustering	O
of	O
colorectal	O
cancer	O
but	O
without	O
germ	O
line	O
mutations	O
in	O
CRC	O
genes	O
have	O
been	O
under	O
surveillance	O
in	O
Leiden	O
since	O
the	O
1980s	O
.	O

Due	O
to	O
the	O
long	O
period	O
of	O
follow	O
-	O
up	O
,	O
with	O
three	O
to	O
four	O
affected	O
generations	O
,	O
these	O
Dutch	O
HNPCC	O
-	O
like	O
families	O
have	O
become	O
informative	O
for	O
linkage	O
analysis	O
.	O

Traditionally	O
,	O
linkage	O
analysis	O
is	O
performed	O
with	O
multi	O
-	O
allelic	O
microsatellite	O
markers	O
.	O

Recently	O
,	O
however	O
,	O
the	O
more	O
advanced	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
arrays	O
were	O
brought	O
into	O
use	O
for	O
linkage	O
analysis	O
.	O

It	O
was	O
shown	O
that	O
the	O
information	O
content	O
of	O
a	O
dense	O
SNP	O
map	O
is	O
significantly	O
and	O
uniformly	O
higher	O
than	O
that	O
of	O
a	O
genome	O
wide	O
microsatellite	O
marker	O
map	O
[	O
21	O
]	O
.	O

Several	O
studies	O
conducting	O
linkage	O
analysis	O
on	O
genotype	O
data	O
from	O
SNP	O
arrays	O
appeared	O
in	O
recent	O
years	O
[	O
22	O
-	O
24	O
]	O
.	O

In	O
these	O
studies	O
non	O
-	O
parametric	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
was	O
performed	O
in	O
sib	O
pairs	O
or	O
in	O
small	O
to	O
moderate	O
size	O
pedigrees	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
studies	O
have	O
been	O
published	O
on	O
linkage	O
analysis	O
using	O
SNPs	O
in	O
large	O
pedigrees	O
(	O
e.g.	O
>	O
35–40	O
bits	O
)	O
.	O

Studying	O
large	O
families	O
with	O
thousands	O
of	O
SNPs	O
results	O
in	O
a	O
computational	O
complex	O
analysis	O
that	O
is	O
challenging	O
for	O
existing	O
statistical	O
packages	O
and	O
that	O
may	O
even	O
exceed	O
their	O
capacity	O
.	O

Current	O
linkage	O
analysis	O
programs	O
can	O
handle	O
either	O
large	O
pedigrees	O
or	O
large	O
numbers	O
of	O
markers	O
,	O
depending	O
on	O
the	O
underlying	O
algorithm	O
.	O

In	O
order	O
to	O
perform	O
linkage	O
analysis	O
in	O
large	O
pedigrees	O
using	O
SNP	O
arrays	O
,	O
we	O
explored	O
the	O
possibilities	O
of	O
currently	O
available	O
linkage	O
analysis	O
software	O
.	O

Most	O
currently	O
available	O
programs	O
are	O
based	O
on	O
the	O
Lander	O
-	O
Green	O
or	O
the	O
Elston	O
-	O
Stewart	O
algorithm	O
or	O
both	O
.	O

The	O
computation	O
time	O
of	O
the	O
former	O
algorithm	O
increases	O
exponentially	O
with	O
the	O
number	O
of	O
bits	O
(	O
2n	O
-	O
f	O
,	O
where	O
'	O
n	O
'	O
is	O
the	O
number	O
of	O
non	O
-	O
founders	O
and	O
'	O
f	O
'	O
the	O
number	O
of	O
founders	O
)	O
in	O
a	O
pedigree	O
,	O
whereas	O
the	O
latter	O
scales	O
exponentially	O
with	O
the	O
number	O
of	O
markers	O
.	O

To	O
perform	O
multipoint	O
linkage	O
analysis	O
in	O
a	O
large	O
family	O
with	O
SNP	O
arrays	O
in	O
one	O
run	O
would	O
probably	O
take	O
several	O
months	O
computation	O
time	O
,	O
if	O
at	O
all	O
possible	O
.	O

Statistics	O
Significance	O
values	O
were	O
calculated	O
using	O
the	O
software	O
package	O
SPSS	O
10.0.7	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Methods	O
Colorectal	O
cancer	O
samples	O
Samples	O
of	O
colorectal	O
cancer	O
tissue	O
and	O
matched	O
normal	O
colonic	O
mucosa	O
were	O
obtained	O
from	O
fresh	O
surgical	O
specimens	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

Thirty	O
nine	O
carcinomas	O
,	O
23	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
and	O
16	O
with	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
were	O
analyzed	O
in	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
clinico	O
-	O
pathological	O
features	O
of	O
the	O
tumors	O
are	O
detailed	O
in	O
Table	O
1	O
.	O

MSI	O
status	O
was	O
determined	O
with	O
a	O
fluorescence	O
-	O
based	O
PCR	O
method	O
,	O
using	O
the	O
five	O
markers	O
of	O
the	O
panel	O
of	O
Bethesda	O
(	O
BAT25	O
,	O
BAT26	O
,	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
[	O
42	O
]	O
.	O

PCR	O
products	O
were	O
run	O
in	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
Division	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
the	O
GeneScan	O
3.1	O
version	O
software	O
(	O
Perkin	O
-	O
Elmer	O
)	O
[	O
43	O
]	O
.	O

According	O
to	O
the	O
guidelines	O
of	O
the	O
Workshop	O
of	O
Bethesda	O
[	O
42	O
]	O
,	O
tumors	O
showing	O
instability	O
at	O
two	O
or	O
more	O
loci	O
were	O
classified	O
as	O
MSI	O
-	O
H	O
and	O
tumors	O
without	O
instability	O
at	O
any	O
locus	O
as	O
MSS	O
.	O

None	O
of	O
the	O
tumors	O
included	O
in	O
this	O
study	O
exhibited	O
instability	O
at	O
a	O
single	O
locus	O
(	O
low	O
-	O
frequency	O
MSI	O
or	O
MSI	O
-	O
L	O
)	O
.	O

All	O
MSI	O
-	O
H	O
carcinomas	O
displayed	O
instability	O
at	O
mononucleotide	O
DNA	O
sequences	O
(	O
BAT25	O
and	O
BAT26	O
markers	O
)	O
.	O

Tumors	O
were	O
also	O
examined	O
for	O
expression	O
of	O
the	O
DNA	O
mismatch	O
repair	O
proteins	O
MLH1	O
and	O
MSH2	O
,	O
using	O
the	O
immunohistochemical	O
analytic	O
procedure	O
previously	O
described	O
[	O
43	O
]	O
.	O

Carcinomas	O
showing	O
complete	O
loss	O
of	O
nuclear	O
MLH1	O
or	O
MSH2	O
expression	O
were	O
classified	O
as	O
MLH1	O
or	O
MSH2	O
negative	O
,	O
whereas	O
cancers	O
with	O
normal	O
expression	O
of	O
MLH1	O
and	O
MSH2	O
gene	O
products	O
were	O
classified	O
as	O
MLH1	O
and	O
MSH2	O
positive	O
.	O

As	O
reported	O
in	O
Table	O
1	O
,	O
all	O
MSS	O
carcinomas	O
demonstrated	O
normal	O
nuclear	O
expression	O
of	O
both	O
MLH1	O
and	O
MSH2	O
proteins	O
(	O
MLH1	O
/	O
MSH2	O
positive	O
)	O
.	O

By	O
contrast	O
,	O
of	O
the	O
16	O
MSI	O
-	O
H	O
tumors	O
15	O
were	O
MLH1	O
negative	O
and	O
one	O
was	O
MSH2	O
negative	O
.	O

As	O
expected	O
,	O
MSI	O
-	O
H	O
carcinomas	O
were	O
more	O
frequently	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
P	O
<	O
0.001	O
)	O
and	O
poorly	O
differentiated	O
(	O
P	O
<	O
0.001	O
)	O
and	O
more	O
often	O
contained	O
a	O
mucinous	O
component	O
(	O
P	O
<	O
0.001	O
)	O
with	O
respect	O
to	O
MSS	O
tumors	O
(	O
Table	O
1	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
following	O
manufacturer	O
's	O
indications	O
.	O

RNA	O
integrity	O
was	O
assessed	O
on	O
a	O
2100	O
Agilent	O
Bioanalyzer	O
.	O

Only	O
samples	O
with	O
intact	O
RNA	O
were	O
used	O
for	O
the	O
gene	O
expression	O
analysis	O
.	O

RNA	O
labeling	O
and	O
microarray	O
hybridization	O
RNA	O
labeling	O
and	O
hybridization	O
on	O
microRNA	O
microarray	O
chips	O
was	O
performed	O
as	O
previously	O
described	O
.	O

[	O
21,22	O
]	O
Briefly	O
,	O
5	O
μg	O
of	O
total	O
RNA	O
from	O
each	O
sample	O
was	O
biotin	O
-	O
labeled	O
by	O
reverse	O
transcription	O
using	O
5	O
'	O
biotin	O
end	O
labeled	O
random	O
examers	O
oligo	O
primer	O
.	O

Hybridization	O
of	O
biotin	O
-	O
labeled	O
cDNA	O
was	O
carried	O
out	O
on	O
our	O
miRNA	O
microarray	O
chip	O
(	O
ArrayExpress	O
accession	O
number	O
:	O
A	O
-	O
MEXP-86	O
)	O
,	O
which	O
contains	O
230	O
human	O
microRNA	O
probes	O
,	O
in	O
triplicate	O
.	O

Hybridization	O
signals	O
were	O
detected	O
by	O
biotin	O
binding	O
of	O
a	O
Streptavidin	O
–	O
Alexa	O
647	O
conjugate	O
using	O
Axon	O
Scanner	O
4000B	O
(	O
Axon	O
Instrument	O
Inc.	O
CA	O
)	O
.	O

Introduction	O
The	O
immune	O
system	O
is	O
thought	O
to	O
have	O
an	O
important	O
function	O
in	O
controlling	O
tumor	O
growth	O
and	O
eliminating	O
metastasizing	O
tumor	O
cells	O
.	O

The	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
class	O
I	O
,	O
presenting	O
tumor	O
-	O
associated	O
antigens	O
on	O
the	O
tumor	O
cell	O
surface	O
,	O
is	O
considered	O
as	O
a	O
prerequisite	O
for	O
an	O
effective	O
T	O
cell	O
immune	O
response	O
[	O
34	O
]	O
.	O

As	O
a	O
consequence	O
,	O
tumor	O
cells	O
with	O
down	O
-	O
regulated	O
HLA	O
class	O
I	O
expression	O
might	O
escape	O
this	O
immune	O
response	O
,	O
resulting	O
in	O
a	O
selective	O
outgrowth	O
of	O
these	O
tumor	O
cells	O
.	O

Many	O
studies	O
described	O
HLA	O
class	O
I	O
expression	O
in	O
cancer	O
[	O
10	O
,	O
17	O
,	O
22	O
,	O
33	O
]	O
.	O

Only	O
limited	O
studies	O
have	O
reported	O
on	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
colorectal	O
cancer	O
with	O
contrasting	O
results	O
.	O

Some	O
studies	O
found	O
no	O
significant	O
correlation	O
between	O
staining	O
intensity	O
and	O
survival	O
[	O
1	O
,	O
19	O
,	O
20	O
]	O
,	O
while	O
others	O
found	O
a	O
prognostic	O
correlation	O
between	O
HLA	O
expression	O
and	O
survival	O
[	O
18	O
,	O
35	O
]	O
.	O

The	O
latter	O
two	O
studies	O
had	O
in	O
common	O
that	O
total	O
absence	O
of	O
HLA	O
class	O
I	O
resulted	O
in	O
a	O
favorable	O
prognosis	O
as	O
compared	O
to	O
patients	O
with	O
down	O
-	O
regulated	O
expression	O
of	O
HLA	O
class	O
I	O
of	O
tumor	O
cells	O
.	O

The	O
discrepancy	O
between	O
these	O
two	O
studies	O
is	O
,	O
whereas	O
the	O
one	O
described	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	O
cells	O
that	O
resulted	O
in	O
a	O
better	O
prognosis	O
as	O
compared	O
to	O
the	O
partial	O
down	O
-	O
regulation	O
of	O
HLA	O
class	O
I	O
[	O
35	O
]	O
,	O
the	O
other	O
found	O
the	O
opposite	O
[	O
18	O
]	O
.	O

These	O
studies	O
both	O
analyzed	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
.	O

For	O
rectal	O
cancer	O
patients	O
,	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
is	O
still	O
unknown	O
.	O

Since	O
HLA	O
class	O
I	O
expression	O
is	O
often	O
absent	O
in	O
microsatellite	O
instable	O
(	O
MSI	O
)	O
tumors	O
[	O
9	O
,	O
16	O
]	O
and	O
MSI	O
is	O
more	O
frequently	O
observed	O
in	O
right	O
-	O
sided	O
colon	O
tumors	O
than	O
in	O
rectal	O
tumors	O
[	O
30	O
]	O
,	O
therefore	O
the	O
results	O
obtained	O
from	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
might	O
not	O
hold	O
true	O
for	O
rectal	O
cancer	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
relevance	O
of	O
HLA	O
class	O
I	O
expression	O
for	O
rectal	O
cancer	O
patients	O
.	O

In	O
addition	O
to	O
determining	O
the	O
impact	O
of	O
MSI	O
on	O
HLA	O
class	O
I	O
expression	O
,	O
the	O
tumors	O
most	O
at	O
risk	O
for	O
MSI	O
i.e.	O
HLA	O
-	O
negative	O
tumors	O
were	O
examined	O
for	O
MSI	O
by	O
determining	O
the	O
expression	O
of	O
the	O
mismatch	O
repair	O
proteins	O
,	O
mismatch	O
mutL	O
homolog	O
1	O
(	O
MLH1	O
)	O
and	O
postmeiotic	O
segregation	O
increased	O
2	O
(	O
PMS2	O
)	O
,	O
that	O
are	O
most	O
absent	O
in	O
sporadic	O
MSI	O
tumors	O
[	O
7	O
,	O
36	O
]	O
.	O

Radiotherapy	O
has	O
been	O
described	O
recently	O
to	O
increase	O
cell	O
surface	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
in	O
a	O
murine	B
colon	O
adenocarcinoma	O
cell	O
line	O
[	O
26	O
]	O
.	O

Therefore	O
,	O
our	O
study	O
also	O
evaluated	O
the	O
effect	O
of	O
radiotherapy	O
on	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
cancer	O
patients	O
.	O

For	O
these	O
purposes	O
,	O
HLA	O
class	O
I	O
expression	O
was	O
evaluated	O
in	O
a	O
set	O
of	O
1,135	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
rectal	O
cancer	O
specimens	O
.	O

The	O
tumors	O
studied	O
were	O
obtained	O
at	O
the	O
time	O
of	O
surgery	O
from	O
patients	O
of	O
a	O
prospective	O
multicenter	O
trial	O
,	O
who	O
were	O
randomized	O
between	O
standardized	O
preoperative	O
radiotherapy	O
treatment	O
followed	O
by	O
surgery	O
or	O
surgery	O
alone	O
[	O
15	O
]	O
.	O

Expression	O
of	O
HLA	O
class	O
I	O
in	O
rectal	O
cancer	O
using	O
HCA2	O
and	O
HC10	O
antibodies	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
χ2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
χ2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	O
class	O
I	O
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	O
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
HLA	O
class	O
I	O
negative	O
cells	O
and	O
microsatellite	O
instability	O
It	O
has	O
been	O
described	O
that	O
a	O
majority	O
of	O
MSI	O
colorectal	O
tumors	O
do	O
not	O
express	O
HLA	O
class	O
I	O
,	O
while	O
only	O
a	O
minority	O
of	O
MSS	O
tumors	O
do	O
not	O
express	O
HLA	O
class	O
I	O
[	O
8	O
,	O
16	O
]	O
.	O

Therefore	O
,	O
HLA	O
class	O
I	O
negative	O
rectal	O
tumors	O
are	O
the	O
most	O
at	O
risk	O
to	O
be	O
MSI	O
tumors	O
.	O

To	O
evaluate	O
the	O
numbers	O
of	O
sporadic	O
MSI	O
tumors	O
in	O
our	O
study	O
,	O
HCA2	O
or	O
HC10	O
negative	O
tumors	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
PMS2	O
and	O
MLH1	O
.	O

PMS2	O
and	O
MLH1	O
are	O
mismatch	O
repairs	O
proteins	O
that	O
are	O
most	O
frequently	O
absent	O
in	O
MSI	O
sporadic	O
tumors	O
[	O
6	O
]	O
.	O

Of	O
the	O
HLA	O
class	O
I	O
negative	O
tumors	O
only	O
1	O
out	O
of	O
11	O
tumors	O
did	O
not	O
express	O
PMS2	O
and	O
MLH1	O
.	O

In	O
the	O
tumor	O
group	O
negative	O
for	O
only	O
1	O
of	O
the	O
2	O
HLA	O
class	O
I	O
markers	O
,	O
2	O
of	O
81	O
tumors	O
displayed	O
no	O
PMS2	O
and	O
MLH1	O
staining	O
.	O

These	O
results	O
indicate	O
that	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
is	O
not	O
associated	O
with	O
MSI	O
in	O
rectal	O
cancer	O
and	O
are	O
in	O
accordance	O
with	O
the	O
previous	O
findings	O
that	O
only	O
a	O
very	O
small	O
minority	O
of	O
rectal	O
tumors	O
are	O
MSI	O
[	O
4	O
,	O
25	O
]	O
.	O

HLA	O
class	O
I	O
expression	O
and	O
clinicopathological	O
parameters	O
The	O
relationship	O
between	O
HLA	O
class	O
I	O
expression	O
and	O
patient	O
/	O
tumor	O
characteristics	O
was	O
assessed	O
(	O
Table	O
3	O
)	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
levels	O
were	O
distributed	O
equally	O
in	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
with	O
regard	O
to	O
most	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Three	O
significant	O
differences	O
were	O
observed	O
.	O

For	O
the	O
non	O
-	O
irradiated	O
patients	O
,	O
significantly	O
more	O
men	O
appeared	O
in	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
group	O
of	O
irradiated	O
tumors	O
with	O
HLA	O
class	O
I	O
low	O
expression	O
contained	O
significantly	O
more	O
stage	O
III	O
and	O
IV	O
tumors	O
(	O
P	O
=	O
0.01	O
)	O
and	O
also	O
more	O
patients	O
with	O
a	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margin	O
(	O
P	O
=	O
0.02	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Table	O
3Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
Non	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
N	O
=	O
445Low	O
N	O
=	O
87P	O
valueHigh	O
N	O
=	O
406Low	O
N	O
=	O
70P	O
valueGender	O
Male	O
(	O
%	O
)	O
63750.0365660.90Age	O
Median	O
years65680.3265650.99TNM	O
stage	O
(	O
%	O
)	O
I31240.5233240.01	O
II27303021	O
III36383240	O
IV58514Circumferential	O
margin	O
Negative	O
(	O
%	O
)	O
83770.2886740.02Distant	O
from	O
anal	O
verge	O
(	O
%	O
)	O
≥10	O
cm28330.1727320.30	O
5–10	O
cm41314636	O
<	O
5	O
cm31362732Operation	O
type	O
(	O
%	O
)	O
Low	O
anterior	O
resection66610.7765660.89	O
Abdomino	O
-	O
perineal	O
resection29332930	O
Hartmann5664Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O

*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Expression	O
of	O
HLA	O
class	O
I	O
and	O
clinical	O
prognosis	O
Because	O
radiotherapy	O
might	O
influence	O
local	O
tumor	O
recurrences	O
[	O
15	O
]	O
,	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
were	O
analyzed	O
separately	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
on	O
tumor	O
recurrence	O
and	O
patient	O
survival	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
was	O
not	O
related	O
with	O
distant	O
or	O
local	O
recurrence	O
rates	O
.	O

The	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
with	O
HLA	O
class	O
I	O
high	O
expression	O
,	O
irrespective	O
of	O
treatment	O
(	O
Fig.	O
2	O
;	O
overall	O
survival	O
:	O
P	O
=	O
0.008	O
and	O
P	O
=	O
0.01	O
;	O
disease	O
free	O
survival	O
:	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.006	O
in	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
,	O
respectively	O
)	O
.	O

Irradiated	O
patients	O
with	O
low	O
HLA	O
class	O
I	O
expression	O
also	O
had	O
a	O
worse	O
cancer	O
-	O
specific	O
survival	O
(	O
P	O
=	O
0.003	O
)	O
.	O

For	O
non	O
-	O
irradiated	O
patients	O
,	O
HLA	O
class	O
I	O
expression	O
had	O
no	O
significant	O
effect	O
on	O
cancer	O
-	O
specific	O
survival	O
(	O
Fig.	O
2	O
)	O
.	O

All	O
results	O
of	O
univariate	O
analysis	O
are	O
shown	O
in	O
Table	O
4	O
.	O

Univariate	O
analysis	O
showed	O
a	O
better	O
outcome	O
for	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Fig.	O
2Examples	O
of	O
Kaplan	O
–	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	O
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
–	O
d	O
)	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	O
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analysesTable	O
4Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
have	O
a	O
better	O
overall	O
,	O
and	O
disease	O
free	O
survivalNon	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueOverall	O
survival65.558.50.01267.551.30.008Disease	O
free	O
survival62.253.50.01562.248.30.006Cancer	O
specific	O
survival74.371.40.4180.161.80.003Local	O
recurrence8.913.70.224.73.20.72Distant	O
recurrence26.728.70.8824.729.30.34Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	O
free	O
survival	O
,	O
cancer	O
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Discussion	O
We	O
showed	O
that	O
rectal	O
cancer	O
patients	O
from	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
had	O
an	O
independent	O
worse	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
from	O
the	O
HLA	O
class	O
I	O
high	O
-	O
expression	O
group	O
.	O

These	O
data	O
imply	O
that	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	O
cells	O
predicts	O
survival	O
for	O
rectal	O
cancer	O
patients	O
.	O

Although	O
significant	O
better	O
cancer	O
-	O
specific	O
survival	O
for	O
irradiated	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
was	O
found	O
in	O
univariate	O
analysis	O
,	O
the	O
predictive	O
value	O
was	O
lost	O
in	O
multivariate	O
analysis	O
.	O

This	O
observation	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
the	O
group	O
with	O
low	O
HLA	O
class	O
I	O
significantly	O
included	O
more	O
stage	O
III	O
/	O
IV	O
and	O
more	O
patients	O
with	O
a	O
positive	O
circumferential	O
margin	O
as	O
compared	O
to	O
the	O
group	O
of	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I.	O
Also	O
no	O
predictive	O
value	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
found	O
with	O
regard	O
to	O
recurrence	O
-	O
free	O
survival	O
of	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
have	O
no	O
indications	O
that	O
support	O
the	O
notion	O
that	O
better	O
survival	O
of	O
high	O
HLA	O
class	O
I	O
expression	O
is	O
due	O
to	O
the	O
better	O
antigen	O
presenting	O
function	O
of	O
these	O
tumor	O
cells	O
,	O
as	O
has	O
been	O
suggested	O
[	O
18	O
,	O
35	O
]	O
.	O

In	O
our	O
study	O
,	O
no	O
difference	O
was	O
found	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
tumor	O
cells	O
.	O

It	O
has	O
been	O
described	O
that	O
γ	O
-	O
irradiation	O
induces	O
enhanced	O
peptide	O
production	O
and	O
surface	O
expression	O
of	O
MHC	O
class	O
I	O
in	O
a	O
colorectal	O
mouse	B
tumor	O
cell	O
line	O
[	O
26	O
]	O
.	O

The	O
fact	O
that	O
we	O
could	O
not	O
find	O
more	O
HLA	O
class	O
I	O
expression	O
in	O
irradiated	O
tumors	O
than	O
in	O
non	O
-	O
irradiated	O
tumors	O
indicates	O
that	O
radiotherapy	O
does	O
not	O
induce	O
HLA	O
class	O
I	O
expression	O
in	O
vivo	O
.	O

Immunohistochemistry	O
,	O
however	O
,	O
is	O
less	O
suitable	O
to	O
measure	O
subtle	O
expression	O
changes	O
.	O

Therefore	O
,	O
additional	O
research	O
is	O
required	O
to	O
determine	O
the	O
impact	O
of	O
radiotherapy	O
on	O
expression	O
levels	O
of	O
HLA	O
class	O
I	O
in	O
human	B
tumors	O
.	O

In	O
our	O
study	O
,	O
more	O
tumors	O
showed	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
after	O
immunohistochemical	O
staining	O
using	O
HCA2	O
than	O
using	O
HC10	O
.	O

This	O
difference	O
might	O
be	O
due	O
to	O
differences	O
in	O
reactivity	O
spectrum	O
of	O
both	O
antibodies	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
or	O
to	O
the	O
fact	O
that	O
HLA	O
alleles	O
are	O
differently	O
affected	O
in	O
colorectal	O
cancer	O
.	O

If	O
the	O
latter	O
is	O
the	O
case	O
,	O
our	O
results	O
suggest	O
that	O
HLA	O
A	O
alleles	O
preferentially	O
show	O
down	O
-	O
regulation	O
in	O
rectal	O
cancer	O
.	O

Previous	O
reports	O
evaluated	O
HLA	O
class	O
I	O
expression	O
in	O
mixed	O
patient	O
populations	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
[	O
18	O
,	O
35	O
]	O
.	O

Watson	O
et	O
al.	O
also	O
found	O
in	O
a	O
large	O
group	O
of	O
colorectal	O
cancer	O
patients	O
that	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
poor	O
prognosis	O
[	O
35	O
]	O
.	O

However	O
,	O
in	O
contrast	O
to	O
our	O
results	O
,	O
both	O
studies	O
described	O
a	O
substantial	O
population	O
of	O
patients	O
with	O
tumors	O
showing	O
absence	O
of	O
HLA	O
class	O
I.	O
In	O
addition	O
,	O
they	O
described	O
that	O
absence	O
of	O
HLA	O
class	O
I	O
was	O
associated	O
with	O
better	O
prognosis	O
as	O
compared	O
to	O
tumors	O
expressing	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

A	O
relatively	O
low	O
number	O
(	O
1.1	O
%	O
)	O
of	O
HLA	O
class	O
I	O
negative	O
tumors	O
was	O
observed	O
in	O
our	O
cohort	O
of	O
rectal	O
cancer	O
patients	O
only	O
.	O

These	O
patients	O
showed	O
no	O
survival	O
advantage	O
when	O
compared	O
to	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

There	O
are	O
several	O
explanations	O
for	O
the	O
discrepancy	O
in	O
the	O
number	O
of	O
HLA	O
class	O
I	O
negative	O
tumors	O
between	O
the	O
study	O
of	O
Watson	O
et	O
al.	O
and	O
ours	O
,	O
like	O
different	O
definition	O
of	O
HLA	O
class	O
I	O
expression	O
,	O
differences	O
in	O
staining	O
techniques	O
,	O
different	O
patient	O
cohort	O
and	O
number	O
of	O
MSI	O
tumors	O
.	O

Both	O
human	B
CRCs	O
and	O
mouse	B
colon	O
tumors	O
reactivate	O
an	O
embryonic	O
gene	O
signature	O
.	O

When	O
human	B
and	O
murine	B
tumors	O
are	O
compared	O
,	O
they	O
both	O
broadly	O
re	O
-	O
express	O
an	O
embryonic	O
gene	O
expression	O
pattern	O
.	O

Gene	O
expression	O
profiles	O
from	O
the	O
mouse	B
tumor	O
models	O
and	O
human	B
CRC	O
samples	O
were	O
combined	O
into	O
a	O
single	O
non	O
-	O
redundant	O
gene	O
ortholog	O
genome	O
table	O
structure	O
and	O
subjected	O
to	O
comparative	O
profile	O
analysis	O
.	O

Informative	O
probe	O
-	O
sets	O
from	O
human	O
and	O
mouse	O
platforms	O
were	O
selected	O
,	O
mapped	O
to	O
corresponding	O
ortholog	O
genes	O
,	O
and	O
used	O
to	O
populate	O
a	O
table	O
in	O
which	O
normalized	O
expression	O
for	O
each	O
gene	O
is	O
relative	O
to	O
normal	O
adult	O
colon	O
.	O

(	O
a	O
)	O
Heatmap	O
plot	O
for	O
all	O
cross	O
-	O
species	O
gene	O
orthologs	O
both	O
present	O
and	O
successfully	O
measured	O
on	O
both	O
the	O
Affymetrix	O
Hg	O
-	O
U133	O
and	O
Vanderbilt	O
Mouse	O
NIA	O
20	O
K	O
microarrays	O
(	O
n	O
=	O
8,621	O
features	O
)	O
.	O

This	O
representation	O
suggests	O
that	O
a	O
large	O
number	O
of	O
human	B
CRC	O
signatures	O
exhibit	O
similar	O
behaviors	O
in	O
the	O
mouse	B
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
(	O
sidebar	O
:	O
1,080	O
(	O
red	O
)	O
and	O
431	O
(	O
green	O
)	O
gene	O
lists	O
from	O
(	O
b	O
)	O
)	O
.	O

(	O
b	O
)	O
Based	O
on	O
results	O
in	O
(	O
a	O
)	O
,	O
four	O
separate	O
gene	O
lists	O
were	O
generated	O
with	O
criteria	O
of	O
over-	O
or	O
under	O
-	O
expression	O
in	O
development	O
or	O
over	O
-	O
expression	O
or	O
under	O
-	O
expression	O
in	O
human	B
CRCs	O
(	O
2,718	O
,	O
2,365	O
,	O
2,212	O
,	O
and	O
737	O
,	O
respectively	O
,	O
with	O
the	O
overlaps	O
shown	O
as	O
a	O
sidebar	O
in	O
(	O
a	O
)	O
;	O
red	O
,	O
1,080	O
transcripts	O
,	O
and	O
green	O
,	O
431	O
transcripts	O
)	O
.	O

Genes	O
over	O
-	O
expressed	O
and	O
under	O
-	O
expressed	O
in	O
embryonic	O
mouse	O
colon	O
and	O
human	B
CRCs	O
were	O
found	O
to	O
be	O
over	O
-	O
represented	O
as	O
determined	O
by	O
Fisher	O
's	O
exact	O
test	O
analysis	O
(	O
*	O
p	O
<	O
7	O
×	O
10	O
-	O
88	O
,	O
*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
,	O

*	O

*	O
*	O
p	O
<	O
5	O
×	O
10	O
-	O
4	O
,	O

*	O

*	O

*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
)	O
.	O

(	O
c	O
)	O
Heatmap	O
plot	O
of	O
all	O
genes	O
co	O
-	O
regulated	O
in	O
human	B
CRCs	O
and	O
during	O
early	O
(	O
ED	O
)	O
and	O
late	O
(	O
LD	O
)	O
mouse	O
embryonic	O
colon	O
development	O
(	O
n	O
=	O
2,216	O
features	O
)	O
.	O

Six	O
predominant	O
clusters	O
(	O
C18-C23	O
)	O
characterize	O
the	O
transcriptional	O
relationship	O
between	O
human	B
CRC	O
and	O
mouse	B
colon	O
tumor	O
models	O
and	O
embryonic	O
development	O
.	O

Two	O
clusters	O
(	O
C20	O
and	O
21	O
)	O
primarily	O
distinguish	O
human	B
CRCs	O
from	O
murine	B
tumors	O
(	O
A	O
,	O
M	O
,	O
S	O
and	O
T	O
)	O
.	O

For	O
example	O
,	O
CRC	O
up	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
developmentally	O
up-	O
or	O
down	O
-	O
regulated	O
are	O
represented	O
by	O
cluster	O
C22	O
(	O
n	O
=	O
860	O
features	O
)	O
and	O
clusters	O
C21	O
/	O
C23	O
(	O
n	O
=	O
142	O
features	O
)	O
,	O
respectively	O
.	O

Conversely	O
,	O
CRC	O
down	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
down-	O
or	O
up	O
-	O
regulated	O
during	O
development	O
are	O
shown	O
in	O
clusters	O
C18	O
/	O
C19	O
(	O
n	O
=	O
258	O
features	O
)	O
and	O
cluster	O
C20	O
(	O
n	O
=	O
42	O
features	O
)	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
approximately	O
80	O
%	O
and	O
approximately	O
60	O
%	O
of	O
genes	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
both	O
human	B
CRCs	O
and	O
mouse	O
development	O
were	O
also	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
tumors	O
from	O
the	O
various	O
mouse	B
models	O
,	O
several	O
clusters	O
provide	O
very	O
interesting	O
exceptions	O
:	O
cluster	O
C20	O
comprises	O
genes	O
down	O
-	O
regulated	O
in	O
human	B
CRCs	O
that	O
are	O
routinely	O
over	O
-	O
expressed	O
in	O
mouse	B
tumors	O
and	O
development	O
;	O
cluster	O
C21	O
comprises	O
genes	O
robustly	O
expressed	O
in	O
human	B
CRC	O
that	O
are	O
rarely	O
expressed	O
in	O
embryonic	O
colon	O
or	O
murine	B
tumors	O
.	O

Sample	O
groups	O
:	O
ED	O
,	O
early	O
development	O
(	O
E13.5-E15.5	O
)	O
;	O
LD	O
,	O
late	O
development	O
(	O
E16.5-E18.5	O
)	O
;	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	O
,	O
human	B
CRC	O
.	O

Staging	O
:	O
nAC	O
,	O
normal	O
colon	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C18-C23	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
PS	O
,	O
ProbeSets	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
.	O

The	O
up	O
-	O
regulated	O
signature	O
in	O
tumors	O
from	O
ApcMin	O
/	O
+	O
(	O
M	O
)	O
and	O
AOM	O
(	O
A	O
)	O
models	O
(	O
cluster	O
C6	O
,	O
Figure	O
2	O
)	O
is	O
enriched	O
with	O
genes	O
associated	O
with	O
the	O
activation	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
.	O

(	O
a	O
)	O
Schematic	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
showing	O
elements	O
present	O
in	O
cluster	O
C6	O
(	O
gene	O
symbols	O
with	O
gray	O
background	O
)	O
.	O

Key	O
elements	O
of	O
this	O
pathway	O
(	O
Ctnnb1	O
,	O
Lef1	O
,	O
Tcf	O
and	O
Myc	O
)	O
are	O
outlined	O
in	O
blue	O
.	O

(	O
b	O
)	O
Relative	O
gene	O
expression	O
for	O
MYC	O
and	O
SOX4	O
is	O
plotted	O
for	O
individual	O
murine	B
and	O
human	B
tumors	O
.	O

The	O
relative	O
expression	O
level	O
of	O
MYC	O
and	O
SOX4	O
is	O
normalized	O
to	O
adult	O
colon	O
.	O

Note	O
that	O
whereas	O
Sox4	O
,	O
a	O
canonical	O
WNT	O
target	O
gene	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
all	O
human	B
CRCs	O
,	O
A	O
/	O
M	O
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
,	O
it	O
is	O
not	O
expressed	O
in	O
Smad3-	O
/	O
-	O
(	O
S	O
)	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
(	O
T	O
)	O
tumors	O
(	O
black	O
)	O
.	O

In	O
contrast	O
,	O
MYC	O
is	O
over	O
-	O
expressed	O
in	O
all	O
human	B
and	O
murine	B
tumors	O
and	O
during	O
colonic	O
embryonic	O
development	O
(	O
red	O
)	O
,	O
irrespective	O
of	O
the	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
(	O
Figure	O
2	O
)	O
.	O

Tissue	O
groups	O
:	O
as	O
above	O
and	O
:	O
nAC	O
-	O
m	O
,	O
normal	O
adult	O
mouse	B
colon	O
;	O
nAC	O
-	O
h	O
,	O
normal	O
adult	O
human	B
colon	O
;	O
Dev	O
,	O
developing	O
mouse	O
colon	O
.	O

Materials	O
and	O
methods	O
Individuals	O
and	O
study	O
samples	O
The	O
research	O
was	O
completed	O
in	O
compliance	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

The	O
Ethics	O
of	O
Human	O
Research	O
Committee	O
of	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
approved	O
the	O
study	O
(	O
approval	O
number	O
02	O
/	O
70	O
)	O
.	O

Individuals	O
used	O
in	O
the	O
study	O
were	O
enrolled	O
in	O
the	O
Kathleen	O
Cuningham	O
Consortium	O
for	O
Research	O
in	O
Familial	O
Breast	O
Cancer	O
(	O
kConFab	O
)	O
.	O

kConFab	O
identified	O
seven	O
breast	O
cancer	O
cases	O
(	O
KCF1	O
-	O
7	O
)	O
with	O
BRCA1-like	O
features	O
for	O
analysis	O
.	O

kConFab	O
provided	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
each	O
case	O
and	O
DNA	O
from	O
buccal	O
mucosa	O
of	O
patient	O
KCF3	O
.	O

Tumour	O
material	O
from	O
the	O
KCF1	O
,	O
KCF2	O
,	O
KCF3	O
,	O
KCF4	O
and	O
KCF6	O
cases	O
was	O
available	O
.	O

Four	O
unstained	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
sections	O
from	O
each	O
tumour	O
were	O
provided	O
for	O
analysis	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
paraffin	O
sections	O
using	O
the	O
DNeasy	O
tissue	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Normal	O
control	O
DNAs	O
were	O
provided	O
by	O
the	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
tissue	O
bank	O
.	O

Methylation	O
analysis	O
CpGenome	O
Universal	O
Methylated	O
DNA	O
(	O
Chemicon	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
100	O
%	O
methylated	O
control	O
and	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
normal	O
individuals	O
was	O
used	O
as	O
unmethylated	O
control	O
DNA	O
.	O

Bisulfite	O
modification	O
of	O
DNA	O
was	O
performed	O
with	O
the	O
MethylEasy	O
kit	O
(	O
Human	O
Genetic	O
Signatures	O
,	O
Sydney	O
,	O
Australia	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Methylation	O
standards	O
were	O
constructed	O
by	O
diluting	O
100	O
%	O
methylated	O
control	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
in	O
a	O
pool	O
of	O
normal	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
at	O
50	O
%	O
,	O
25	O
%	O
,	O
10	O
%	O
,	O
5	O
%	O
and	O
1	O
%	O
ratios	O
.	O

Methylation	O
of	O
the	O
BRCA1	O
promoter	O
was	O
assessed	O
using	O
real	O
-	O
time	O
methylation	O
specific	O
PCR	O
(	O
MethyLight	O
)	O
[	O
19	O
]	O
and	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
[	O
20	O
]	O
.	O

All	O
samples	O
were	O
run	O
in	O
triplicate	O
for	O
each	O
assay	O
.	O

The	O
locations	O
of	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
primers	O
and	O
probes	O
on	O
the	O
BRCA1	O
promoter	O
are	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
MethyLight	O
assay	O
assessed	O
five	O
CpG	O
sites	O
and	O
the	O
MS	O
-	O
HRM	O
assay	O
assessed	O
four	O
sites	O
.	O

Careful	O
design	O
of	O
each	O
assay	O
was	O
required	O
to	O
avoid	O
amplification	O
from	O
the	O
BRCA1	O
pseudogene	O
.	O

The	O
HMBS	O
gene	O
was	O
used	O
as	O
a	O
control	O
for	O
the	O
BRCA1	O
MethyLight	O
assay	O
.	O

Primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Map	O
of	O
the	O
BRCA1	O
promoter	O
region	O
studied	O
by	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
assays	O
.	O

The	O
numbering	O
of	O
the	O
promoter	O
is	O
according	O
to	O
that	O
used	O
by	O
Rice	O
et	O
al.	O
[	O
24	O
]	O
.	O

TSS	O
denotes	O
the	O
transcription	O
start	O
site	O
.	O

The	O
positions	O
of	O
the	O
primers	O
flanking	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
amplicons	O
are	O
indicated	O
as	O
well	O
as	O
the	O
position	O
of	O
the	O
MethyLight	O
probe	O
.	O

Experiments	O
were	O
performed	O
on	O
the	O
RotorGene	O
™	O
3000	O
(	O
MethyLight	O
assays	O
)	O
and	O
RotorGene	O
™	O
6000	O
(	O
MS	O
-	O
HRM	O
assays	O
)	O
instruments	O
(	O
Corbett	O
Research	O
,	O
Sydney	O
,	O
Australia	O
)	O
.	O

The	O
MethyLight	O
data	O
was	O
analysed	O
by	O
obtaining	O
the	O
take	O
-	O
off	O
(	O
Ct	O
)	O
and	O
amplification	O
efficiency	O
values	O
for	O
each	O
sample	O
for	O
BRCA1	O
and	O
HMBS	O
from	O
the	O
comparative	O
quantitation	O
tab	O
of	O
the	O
RotorGene	O
™	O
analysis	O
software	O
and	O
comparing	O
them	O
to	O
the	O
values	O
for	O
the	O
100	O
%	O
methylated	O
DNA	O
according	O
to	O
the	O
Pfaffl	O
method	O
of	O
relative	O
quantification	O
[	O
21	O
]	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
Ingenuity	O
Systems	O
,	O
www.ingenuity.com	O
)	O
was	O
used	O
for	O
biological	O
interpretation	O
of	O
gene	O
lists	O
.	O

Analysis	O
of	O
the	O
transcripts	O
found	O
to	O
be	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
irradiated	O
LCLs	O
as	O
identified	O
for	O
the	O
different	O
mutation	O
categories	O
identified	O
those	O
biochemical	O
networks	O
most	O
likely	O
to	O
be	O
affected	O
by	O
a	O
BRCA1	O
and	O
BRCA2	O
truncating	O
and	O
missense	O
mutation	O
,	O
relative	O
to	O
BRCAX	O
.	O

Those	O
pathways	O
with	O
multiple	O
hits	O
or	O
a	O
significance	O
score	O
≥20	O
were	O
then	O
compared	O
.	O

Methods	O
Patients	O
Between	O
1957	O
and	O
31	O
December	O
2004	O
the	O
Swedish	O
Polyposis	O
Registry	O
included	O
data	O
on	O
196	O
families	O
with	O
verified	O
FAP	O
(	O
defined	O
as	O
more	O
than	O
100	O
colorectal	O
adenomas	O
or	O
if	O
less	O
with	O
a	O
family	O
history	O
of	O
FAP	O
)	O
.	O

Sixty	O
-	O
one	O
of	O
these	O
families	O
are	O
now	O
extinct	O
but	O
135	O
families	O
with	O
at	O
least	O
one	O
living	O
disease	O
-	O
affected	O
member	O
remain	O
.	O

Presently	O
,	O
315	O
disease	O
-	O
affected	O
living	O
patients	O
are	O
included	O
in	O
the	O
registry	O
.	O

The	O
geographical	O
catchment	O
area	O
comprises	O
the	O
whole	O
of	O
Sweden	O
.	O

Details	O
of	O
how	O
patients	O
have	O
been	O
eligible	O
for	O
accession	O
into	O
the	O
registry	O
are	O
given	O
in	O
[	O
30	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
96	O
families	O
included	O
in	O
the	O
registry	O
for	O
mutations	O
in	O
the	O
APC	O
gene	O
.	O

Twenty	O
-	O
four	O
of	O
the	O
remaining	O
39	O
families	O
have	O
been	O
analyzed	O
for	O
APC	O
gene	O
mutations	O
at	O
other	O
genetic	O
laboratories	O
and	O
15	O
families	O
remain	O
to	O
be	O
tested	O
.	O

We	O
have	O
previously	O
reported	O
six	O
of	O
these	O
patients	O
who	O
carried	O
bi	O
-	O
allelic	O
MUTYH	O
mutations	O
[	O
31	O
]	O
.	O

Probands	O
were	O
defined	O
as	O
those	O
diagnosed	O
on	O
the	O
basis	O
of	O
the	O
occurrence	O
of	O
symptoms	O
and	O
irrespective	O
of	O
other	O
cases	O
in	O
the	O
family	O
and	O
call	O
-	O
up	O
patients	O
,	O
as	O
those	O
identified	O
as	O
subjects	O
at	O
risk	O
on	O
the	O
basis	O
of	O
studies	O
of	O
pedigrees	O
and	O
found	O
to	O
have	O
FAP	O
.	O

De	O
novo	O
mutations	O
were	O
defined	O
in	O
those	O
individuals	O
where	O
none	O
of	O
the	O
parents	O
carried	O
the	O
mutation	O
or	O
where	O
the	O
parents	O
had	O
a	O
negative	O
colonoscopy	O
after	O
the	O
age	O
of	O
50	O
or	O
died	O
of	O
a	O
non	O
-	O
FAP	O
related	O
cause	O
after	O
the	O
age	O
of	O
75	O
.	O

All	O
patients	O
have	O
given	O
their	O
consent	O
and	O
the	O
local	O
ethics	O
committees	O
have	O
approved	O
the	O
study	O
.	O

The	O
clinical	O
features	O
of	O
index	O
patients	O
of	O
each	O
of	O
the	O
families	O
analyzed	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
and	O
Table	O
1	O
.	O

Patients	O
without	O
any	O
detected	O
mutation	O
in	O
APC	O
or	O
MUTYH	O
Age	O
,	O
age	O
at	O
diagnosis	O
;	O
DL	O
,	O
duodenal	O
lesion	O
;	O
dom	O
,	O
dominant	O
;	O
FGP	O
,	O
fundic	O
gland	O
polyps	O
;	O
NA	O
,	O
no	O
available	O
data	O
;	O
NI	O
,	O
no	O
inheritance	O
;	O
Number	O
of	O
polyps	O
,	O
number	O
of	O
polyps	O
at	O
diagnosis	O
;	O
rec	O
,	O
recessive	O
Patient	O
C896	O
,	O
with	O
only	O
five	O
adenomas	O
,	O
was	O
included	O
because	O
of	O
a	O
family	O
history	O
of	O
FAP	O
.	O

Patient	O
C107	O
underwent	O
her	O
first	O
colonoscopy	O
due	O
to	O
intestinal	O
bleeding	O
at	O
age	O
47	O
.	O

At	O
diagnosis	O
,	O
10–20	O
small	O
(	O
less	O
than	O
10	O
mm	O
)	O
polyps	O
were	O
found	O
in	O
most	O
colorectal	O
parts	O
.	O

Tubular	O
and	O
tubulovillous	O
adenomas	O
were	O
removed	O
yearly	O
.	O

At	O
age	O
50	O
,	O
carcinoma	O
(	O
Dukes	O
A	O
)	O
was	O
diagnosed	O
4	O
cm	O
from	O
valvula	O
Bauhini	O
in	O
conjunction	O
with	O
several	O
new	O
adenomas	O
.	O

At	O
that	O
time	O
the	O
patient	O
underwent	O
total	O
colectomy	O
with	O
ileorectal	O
anastomosis	O
(	O
IRA	O
)	O
.	O

DNA	O
,	O
RNA	O
and	O
cDNA	O
preparation	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
samples	O
of	O
venous	O
blood	O
,	O
anti	O
-	O
coagulated	O
in	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
.	O

DNA	O
purification	O
was	O
performed	O
using	O
the	O
PuregeneR	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
as	O
described	O
previously	O
[	O
32	O
]	O
.	O

Histopaque	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
or	O
Lymphoprep	O
(	O
Axis	O
-	O
Shield	O
PoC	O
AS	O
,	O
Oslo	O
,	O
Norway	O
)	O
was	O
used	O
for	O
purification	O
of	O
the	O
lymphocytes	O
,	O
and	O
total	O
RNA	O
was	O
extracted	O
using	O
RNA	O
-	O
Stat	O
60	O
(	O
Tel	O
-	O
Test	O
,	O
Friendswood	O
,	O
TX	O
)	O
.	O

cDNA	O
was	O
synthesized	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

The	O
phenotype	O
of	O
the	O
patient	O
(	O
C157	O
)	O
,	O
carrying	O
the	O
c.70C	O
>	O
T	O
mutation	O
,	O
is	O
in	O
agreement	O
with	O
the	O
suggested	O
genotype	O
-	O
phenotype	O
correlation	O
where	O
a	O
milder	O
form	O
of	O
polyposis	O
is	O
proposed	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
model	O
for	O
the	O
attenuated	O
phenotype	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
of	O
APC	O
have	O
been	O
suggested	O
by	O
Heppner	O
Goss	O
et	O
al	O
[	O
42	O
]	O
,	O
in	O
which	O
the	O
internal	O
ATG	O
at	O
codon	O
184	O
could	O
be	O
used	O
as	O
an	O
alternative	O
translation	O
initiation	O
codon	O
in	O
the	O
allele	O
carrying	O
a	O
truncating	O
mutation	O
upstream	O
of	O
this	O
site	O
(	O
Figure	O
1	O
)	O
.	O

Such	O
an	O
alternative	O
start	O
of	O
translation	O
would	O
supply	O
the	O
cell	O
with	O
an	O
APC	O
protein	O
of	O
almost	O
full	O
length	O
,	O
thus	O
explaining	O
the	O
attenuated	O
phenotype	O
.	O

Patient	O
C159	O
,	O
with	O
the	O
most	O
3	O
'	O
localized	O
mutation	O
was	O
a	O
case	O
of	O
attenuated	O
FAP	O
(	O
100–1000	O
polyps	O
,	O
46	O
years	O
of	O
age	O
at	O
diagnosis	O
)	O
.	O

In	O
family	O
1	O
(	O
reduced	O
expression	O
of	O
APC	O
)	O
,	O
patient	O
C152	O
displayed	O
a	O
classical	O
FAP	O
phenotype	O
including	O
a	O
large	O
number	O
of	O
polyps	O
,	O
duodenal	O
adenomas	O
,	O
and	O
fundic	O
gland	O
polyps	O
(	O
Additional	O
file	O
1	O
)	O
.	O

The	O
APC-	O
and	O
MUTYH	O
-	O
mutation	O
negative	O
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	O
with	O
a	O
low	O
number	O
of	O
polyps	O
,	O
comparably	O
high	O
age	O
at	O
diagnosis	O
,	O
and	O
a	O
low	O
frequency	O
of	O
extracolonic	O
manifestations	O
.	O

Whether	O
these	O
patients	O
really	O
are	O
affected	O
by	O
APC	O
-	O
associated	O
FAP	O
can	O
(	O
of	O
course	O
)	O
be	O
called	O
into	O
question	O
.	O

However	O
,	O
among	O
attenuated	O
cases	O
of	O
FAP	O
in	O
these	O
study	O
we	O
have	O
found	O
very	O
subtle	O
mutations	O
such	O
as	O
the	O
mosaic	O
case	O
as	O
well	O
as	O
the	O
c.70C	O
>	O
T	O
mutation	O
and	O
splice	O
-	O
site	O
mutations	O
.	O

Considering	O
these	O
facts	O
,	O
at	O
least	O
some	O
of	O
the	O
cases	O
could	O
be	O
caused	O
by	O
mutations	O
in	O
APC	O
resulting	O
in	O
only	O
partially	O
inactivation	O
of	O
the	O
gene	O
function	O
.	O

Since	O
the	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
achieve	O
as	O
high	O
mutation	O
-	O
detection	O
rate	O
as	O
possible	O
in	O
families	O
with	O
colorectal	O
polyposis	O
syndromes	O
,	O
using	O
a	O
range	O
of	O
different	O
molecular	O
genetic	O
techniques	O
,	O
we	O
have	O
not	O
yet	O
performed	O
any	O
further	O
analyses	O
of	O
the	O
relatively	O
few	O
mutation	O
negative	O
cases	O
to	O
determine	O
if	O
they	O
belong	O
to	O
non	O
-	O
polyposis	O
CRC	O
syndromes	O
.	O

Large	O
deletions	O
of	O
the	O
APC	O
gene	O
The	O
fraction	O
of	O
large	O
deletions	O
of	O
all	O
APC	O
mutations	O
identified	O
in	O
the	O
Swedish	O
patients	O
was	O
9	O
%	O
,	O
which	O
is	O
higher	O
than	O
the	O
5	O
%	O
of	O
large	O
deletions	O
reported	O
in	O
[	O
38	O
]	O
.	O

The	O
relatively	O
large	O
number	O
of	O
gross	O
deletions	O
identified	O
could	O
be	O
a	O
result	O
of	O
the	O
thorough	O
analysis	O
applied	O
for	O
every	O
patient	O
,	O
including	O
the	O
use	O
of	O
the	O
MLPA	O
technique	O
.	O

It	O
is	O
noteworthy	O
that	O
no	O
deletion	O
of	O
APC	O
exon	O
4	O
in	O
patient	O
3765	O
was	O
detected	O
using	O
MLPA	O
although	O
it	O
had	O
been	O
identified	O
and	O
confirmed	O
by	O
other	O
methods	O
.	O

A	O
still	O
untested	O
possibility	O
is	O
that	O
exon	O
4	O
has	O
been	O
translocated	O
to	O
another	O
chromosomal	O
locus	O
and	O
thus	O
generates	O
the	O
positive	O
MLPA	O
result	O
.	O

RESULTS	O
MSH6	O
Good	O
quality	O
sequence	O
was	O
obtained	O
for	O
all	O
10	O
exons	O
of	O
MSH6	O
in	O
220	O
participants	O
,	O
115	O
from	O
HNPCC	O
cohort	O
,	O
and	O
105	O
from	O
endometrial	O
cohort	O
.	O

Results	O
with	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
are	O
shown	O
in	O
table	O
I.	O
Given	O
that	O
the	O
pathogenicity	O
of	O
the	O
missense	O
mutations	O
identified	O
has	O
yet	O
to	O
be	O
determined	O
,	O
arguably	O
the	O
proportion	O
of	O
the	O
truncating	O
mutations	O
is	O
more	O
relevant	O
.	O

All	O
sequences	O
were	O
viewed	O
with	O
reference	O
to	O
a	O
control	O
sample	O
(	O
with	O
a	O
known	O
mutation	O
in	O
MLH1	O
or	O
MSH2	O
)	O
,	O
and	O
reference	O
sequences	O
(	O
,	O
)	O
.	O

All	O
variants	O
are	O
described	O
with	O
reference	O
to	O
den	O
Dunnen	O
et	O
al26	O
.	O

All	O
truncating	O
and	O
missense	O
variants	O
identified	O
are	O
shown	O
in	O
tables	O
II	O
and	O
III	O
(	O
example	O
figure	O
1	O
)	O
with	O
their	O
corresponding	O
cohort	O
and	O
family	O
classification	O
.	O

Participants	O
from	O
the	O
endometrial	O
cohort	O
with	O
a	O
variant	O
identified	O
were	O
also	O
classified	O
according	O
to	O
Amsterdam	O
I	O
,	O
II	O
,	O
'	O
HNPCC	O
like	O
'	O
,	O
or	O
,	O
a	O
family	O
history	O
that	O
was	O
not	O
in	O
keeping	O
with	O
HNPCC	O
.	O

All	O
missense	O
variants	O
were	O
subject	O
to	O
analysis	O
by	O
PolyPhen	O
(	O
)	O
,	O
a	O
tool	O
that	O
predicts	O
the	O
potential	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
(	O
see	O
table	O
III	O
for	O
predictions	O
)	O
.	O

Further	O
population	O
,	O
family	O
and	O
functional	O
studies	O
were	O
not	O
carried	O
out	O
to	O
evaluate	O
the	O
missense	O
variants	O
but	O
further	O
work	O
is	O
planned	O
.	O

Sequencing	O
analysis	O
showing	O
a	O
truncating	O
mutation	O
c.755	O
C	O
>	O
G	O
(	O
p.	O

Ser252X	O
)	O
in	O
exon	O
4	O
of	O
MSH6	O
Truncating	O
mutations	O
identified	O
Missense	O
variants	O
identified	O
MLPA	O
All	O
samples	O
underwent	O
MLPA	O
analysis	O
.	O

Out	O
of	O
268	O
successful	O
MLPA	O
results	O
,	O
no	O
aberration	O
in	O
copy	O
number	O
was	O
identified	O
.	O

Methods	O
Cell	O
Culture	O
MCF7	O
,	O
MDA	O
-	O
MB-231	O
,	O
MDA	O
-	O
MB-468	O
,	O
T-47D	O
,	O
HT-29	O
,	O
Caco-2	O
,	O
Colo320	O
,	O
SW480	O
,	O
RKO	O
,	O
and	O
HCT116	O
cells	O
and	O
isogenic	O
DNA	O
methyltransferase	O
(	O
DNMT	O
)	O
1	O
/	O
3b	O
genetic	O
knockout	O
derivatives	O
were	O
maintained	O
in	O
culture	O
as	O
recommended	O
by	O
American	O
Type	O
Tissue	O
Culture	O
(	O
ATCC	O
)	O
.	O

All	O
HCC	O
series	O
lines	O
used	O
were	O
obtained	O
from	O
ATCC	O
.	O

For	O
drug	O
treatments	O
,	O
log	O
phase	O
cells	O
were	O
cultured	O
in	O
the	O
appropriate	O
media	O
(	O
Invitrogen	O
)	O
containing	O
10	O
%	O
FBS	O
and	O
1	O
×	O
penicillin	O
/	O
streptomycin	O
with	O
5	O
μM	O
5aza	O
-	O
deoxycytidine	O
(	O
DAC	O
)	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1	O
mM	O
in	O
PBS	O
)	O
for	O
96	O
h	O
,	O
replacing	O
media	O
and	O
DAC	O
every	O
24	O
h.	O
Cell	O
treatment	O
with	O
300	O
nM	O
Trichostatin	O
A	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1.5	O
mM	O
dissolved	O
in	O
ethanol	O
)	O
was	O
performed	O
for	O
18	O
h.	O
Control	O
cells	O
underwent	O
mock	O
treatment	O
in	O
parallel	O
with	O
addition	O
of	O
equal	O
volume	O
of	O
PBS	O
or	O
ethanol	O
without	O
drugs	O
.	O

Microarray	O
Analysis	O
Total	O
RNA	O
was	O
harvested	O
from	O
log	O
phase	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Sample	O
amplification	O
and	O
labeling	O
procedures	O
were	O
carried	O
out	O
using	O
the	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
kit	O
(	O
Agilent	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
was	O
carried	O
out	O
according	O
to	O
the	O
Agilent	O
microarray	O
protocol	O
.	O

Scanning	O
was	O
performed	O
with	O
the	O
Agilent	O
G2565BA	O
microarray	O
scanner	O
.	O

Data	O
Analysis	O
All	O
arrays	O
were	O
subject	O
to	O
quality	O
checks	O
recommended	O
by	O
the	O
manufacturer	O
.	O

All	O
calculations	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
computing	O
platform	O
[	O
16	O
]	O
and	O
packages	O
from	O
Bioconductor	O
bioinformatics	O
software	O
project	O
[	O
17	O
]	O
.	O

The	O
log	O
ratio	O
of	O
red	O
signal	O
to	O
green	O
signal	O
was	O
calculated	O
after	O
background	O
-	O
subtraction	O
and	O
LoEss	O
normalization	O
as	O
implemented	O
in	O
the	O
limma	O
package	O
from	O
Bioconductor	O
[	O
18	O
]	O
.	O

Individual	O
arrays	O
were	O
scaled	O
to	O
have	O
the	O
same	O
interquartile	O
range	O
(	O
75th	O
percentile	O
to	O
25th	O
percentile	O
)	O
.	O

Patient	O
information	O
,	O
including	O
clinical	O
data	O
and	O
gene	O
expression	O
data	O
,	O
was	O
obtained	O
from	O
and	O
analyzed	O
using	O
Oncomine	O
(	O
http://www.oncomine.org	O
)	O
.	O

Our	O
analysis	O
included	O
microarray	O
databases	O
such	O
as	O
the	O
Netherlands	O
Cancer	O
Institute	O
breast	O
cancer	O
database	O
[	O
19	O
]	O
.	O

The	O
microarray	O
meta	O
-	O
analysis	O
algorithms	O
and	O
statistical	O
analysis	O
used	O
were	O
as	O
previously	O
described	O
[	O
20,21	O
]	O
.	O

p	O
-	O
Values	O
were	O
calculated	O
using	O
adjustment	O
for	O
multiple	O
testing	O
and	O
false	O
discovery	O
as	O
described	O
at	O
http://www.oncomine.org	O
[	O
21	O
]	O
.	O

Methylation	O
and	O
Gene	O
Expression	O
Analysis	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
Reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

For	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
1	O
μg	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
by	O
using	O
Ready	O
-	O
To	O
-	O
Go	O
You	O
-	O
Prime	O
First	O
-	O
Strand	O
Beads	O
(	O
Amersham	O
Biosciences	O
)	O
with	O
addition	O
of	O
random	O
hexamers	O
(	O
0.2	O
μg	O
per	O
reaction	O
)	O
.	O

Bisulfite	O
modification	O
of	O
genomic	O
DNA	O
was	O
carried	O
out	O
using	O
the	O
EZ	O
DNA	O
methylation	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O

Selection	O
of	O
primers	O
used	O
for	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
and	O
determinants	O
for	O
CpG	O
island	O
localization	O
and	O
designation	O
was	O
accomplished	O
using	O
MSPPrimer	O
(	O
http://www.mspprimer.org	O
)	O
[	O
22	O
]	O
.	O

MSP	O
was	O
performed	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

Primer	O
sequences	O
are	O
listed	O
in	O
Table	O
S3	O
.	O

Bisulfite	O
sequencing	O
and	O
RT	O
-	O
PCR	O
was	O
preformed	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O

Gene	O
expression	O
quantitation	O
was	O
performed	O
using	O
RT	O
-	O
PCR	O
and	O
the	O
1D	O
software	O
package	O
(	O
Kodak	O
)	O
.	O

For	O
Table	O
S1	O
,	O
decreased	O
expression	O
was	O
defined	O
as	O
expression	O
that	O
was	O
not	O
detectable	O
with	O
RT	O
-	O
PCR	O
or	O
decreased	O
by	O
two	O
-	O
thirds	O
compared	O
to	O
expression	O
levels	O
in	O
normal	O
tissue	O
measured	O
using	O
the	O
1D	O
software	O
to	O
quantitate	O
bands	O
.	O

Quantitative	O
PCR	O
was	O
performed	O
using	O
the	O
Invitrogen	O
SYBR	O
Green	O
qPCR	O
kit	O
according	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Real	O
-	O
time	O
PCR	O
reactions	O
were	O
performed	O
using	O
the	O
Mastercycler	O
Realplex	O
machine	O
(	O
Eppendorf	O
)	O
.	O

Readings	O
were	O
normalized	O
using	O
GAPDH	O
.	O

Discussion	O
Overall	O
our	O
study	O
presents	O
an	O
extensive	O
search	O
for	O
the	O
presence	O
of	O
and	O
interactions	O
between	O
both	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
cancer	O
.	O

As	O
it	O
currently	O
stands	O
,	O
these	O
studies	O
do	O
have	O
several	O
limitations	O
.	O

First	O
,	O
our	O
data	O
do	O
not	O
address	O
the	O
biological	O
effects	O
of	O
the	O
individual	O
mutations	O
observed	O
in	O
the	O
CAN	O
genes	O
.	O

Second	O
,	O
the	O
data	O
draw	O
on	O
only	O
the	O
13,023	O
subset	O
of	O
CCDS	O
genes	O
that	O
were	O
previously	O
sequenced	O
,	O
and	O
additional	O
genes	O
have	O
now	O
been	O
sequenced	O
and	O
more	O
mutations	O
have	O
been	O
discovered	O
[	O
42	O
]	O
.	O

Despite	O
these	O
limitations	O
,	O
our	O
study	O
describes	O
a	O
valuable	O
approach	O
to	O
begin	O
to	O
understand	O
the	O
biological	O
significance	O
of	O
the	O
vast	O
amount	O
of	O
mutational	O
data	O
generated	O
by	O
cancer	O
resequencing	O
efforts	O
.	O

In	O
these	O
regards	O
,	O
our	O
findings	O
allow	O
several	O
important	O
conclusions	O
to	O
be	O
drawn	O
.	O

First	O
,	O
our	O
study	O
shows	O
that	O
large	O
-	O
scale	O
,	O
combined	O
genetic	O
and	O
epigenetic	O
analysis	O
is	O
feasible	O
and	O
useful	O
for	O
cancer	O
gene	O
discovery	O
.	O

Such	O
combined	O
analyses	O
can	O
markedly	O
enhance	O
links	O
made	O
between	O
gene	O
alterations	O
and	O
key	O
clinical	O
parameters	O
for	O
cancer	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
examination	O
and	O
interpretation	O
of	O
mutations	O
to	O
identify	O
cancer	O
genes	O
on	O
a	O
genome	O
-	O
wide	O
scale	O
can	O
be	O
significantly	O
complicated	O
by	O
passenger	O
mutations	O
[	O
43,44	O
]	O
.	O

Furthermore	O
,	O
as	O
we	O
mentioned	O
above	O
in	O
the	O
Results	O
,	O
it	O
is	O
very	O
unlikely	O
that	O
a	O
given	O
gene	O
that	O
in	O
breast	O
and/or	O
colon	O
cancer	O
has	O
evidence	O
for	O
mutations	O
,	O
promoter	O
hypermethylation	O
,	O
reduced	O
expression	O
,	O
and	O
is	O
localized	O
to	O
chromosome	O
regions	O
harboring	O
frequent	O
deletions	O
in	O
tumors	O
is	O
not	O
important	O
for	O
tumor	O
development	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
by	O
beginning	O
with	O
a	O
large	O
pool	O
of	O
genes	O
harboring	O
mostly	O
low	O
incidence	O
heterozygous	O
missense	O
mutations	O
and	O
then	O
characterizing	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
these	O
genes	O
,	O
our	O
approach	O
allowed	O
us	O
to	O
identify	O
genes	O
that	O
possess	O
potentially	O
prognostic	O
value	O
.	O

Our	O
results	O
also	O
confirm	O
that	O
our	O
microarray	O
strategy	O
is	O
an	O
effective	O
approach	O
to	O
identify	O
genes	O
that	O
are	O
silenced	O
by	O
hypermethylation	O
in	O
colon	O
and	O
breast	O
cancer	O
.	O

Other	O
methods	O
have	O
been	O
developed	O
to	O
identify	O
hypermethylated	O
genes	O
in	O
cancer	O
,	O
including	O
restriction	O
landmark	O
genomic	O
scanning	O
,	O
promoter	O
CpG	O
island	O
microarrays	O
,	O
and	O
methylation	O
-	O
specific	O
digital	O
karyotyping	O
[	O
28,45	O
]	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
these	O
techniques	O
is	O
restricted	O
by	O
the	O
locations	O
of	O
methylation	O
-	O
sensitive	O
restriction	O
sites	O
in	O
the	O
genome	O
.	O

Several	O
of	O
the	O
common	O
target	O
genes	O
have	O
been	O
noted	O
to	O
undergo	O
methylation	O
-	O
associated	O
silencing	O
in	O
cancers	O
by	O
other	O
investigators	O
.	O

Lund	O
et	O
al.	O
noted	O
that	O
oncogenic	O
RAS	O
can	O
lead	O
to	O
the	O
hypermethylation	O
of	O
the	O
MMP2	O
gene	O
[	O
46	O
]	O
.	O

EVL	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
colon	O
carcinoma	O
[	O
47	O
]	O
.	O

N	O
-	O
CAM	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
lung	O
cancer	O
in	O
a	O
survey	O
of	O
methylated	O
genes	O
described	O
by	O
Shames	O
et	O
al.	O
[	O
48	O
]	O
.	O

The	O
presence	O
of	O
methylation	O
of	O
the	O
common	O
target	O
genes	O
in	O
other	O
tumor	O
types	O
suggests	O
that	O
these	O
genes	O
may	O
be	O
targets	O
of	O
inactivation	O
in	O
a	O
broader	O
range	O
of	O
cancers	O
,	O
a	O
hypothesis	O
that	O
warrants	O
future	O
investigation	O
.	O

In	O
particular	O
,	O
it	O
would	O
be	O
of	O
value	O
to	O
directly	O
compare	O
our	O
results	O
with	O
those	O
derived	O
by	O
other	O
strategies	O
for	O
analyzing	O
the	O
hypermethylome	O
from	O
the	O
same	O
as	O
well	O
as	O
from	O
other	O
types	O
of	O
malignancies	O
[	O
48–51	O
]	O
.	O

Together	O
with	O
these	O
studies	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
a	O
compendium	O
of	O
epigenetic	O
changes	O
underlie	O
the	O
progression	O
of	O
human	O
cancers	O
.	O

Stabilizing	O
mutation	O
of	O
/beta	O
-	O
catenin	O
and	O
protein	O
accumulation	O
analyzed	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
tumors	O
of	O
Swedish	O
patients	O
Abstract	O
Background	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
human	B
neoplasms	O
.	O

We	O
recently	O
reported	O
accumulation	O
of	O
β	O
-	O
catenin	O
in	O
parathyroid	O
adenomas	O
from	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
pHPT	O
)	O
.	O

In	O
CTNNB1	O
exon	O
3	O
,	O
we	O
detected	O
a	O
stabilizing	O
mutation	O
(	O
S37A	O
)	O
in	O
3	O
out	O
of	O
20	O
analyzed	O
adenomas	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
zygosity	O
of	O
mutations	O
in	O
CTNNB1	O
exon	O
3	O
,	O
and	O
β	O
-	O
catenin	O
accumulation	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
adenomas	O
of	O
Swedish	O
patients	O
.	O

Results	O
The	O
mutation	O
S37A	O
(	O
TCT	O
>	O
GCT	O
)	O
was	O
detected	O
by	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
fragments	O
in	O
6	O
out	O
of	O
104	O
sporadic	O
parathyroid	O
adenomas	O
(	O
5.8	O
%	O
)	O
.	O

Taking	O
our	O
previous	O
study	O
into	O
account	O
,	O
a	O
total	O
of	O
9	O
out	O
of	O
124	O
(	O
7.3	O
%	O
)	O
adenomas	O
displayed	O
the	O
same	O
mutation	O
.	O

The	O
mutations	O
were	O
homozygous	O
by	O
DNA	O
sequencing	O
,	O
restriction	O
enzyme	O
cleavage	O
,	O
and	O
gene	O
copy	O
number	O
determination	O
using	O
the	O
GeneChip	O
500	O
K	O
Mapping	O
Array	O
Set	O
.	O

All	O
tumors	O
analyzed	O
by	O
immunohistochemistry	O
,	O
including	O
those	O
with	O
mutation	O
,	O
displayed	O
aberrant	O
β	O
-	O
catenin	O
accumulation	O
.	O

Western	O
blotting	O
revealed	O
a	O
slightly	O
higher	O
expression	O
level	O
of	O
β	O
-	O
catenin	O
and	O
nonphosphorylated	O
active	O
β	O
-	O
catenin	O
in	O
tumors	O
with	O
mutation	O
compared	O
to	O
those	O
without	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
not	O
related	O
to	O
distinct	O
clinical	O
characteristics	O
.	O

Conclusion	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
is	O
very	O
common	O
in	O
parathyroid	O
tumors	O
,	O
and	O
is	O
caused	O
by	O
stabilizing	O
homozygous	O
mutation	O
in	O
7.3	O
%	O
of	O
Swedish	O
pHPT	O
patients	O
.	O

Hybridization	O
of	O
the	O
SBE	O
reaction	O
products	O
The	O
slides	O
printed	O
with	O
'	O
anti	O
-	O
tags	O
'	O
were	O
pre	O
-	O
heated	O
to	O
42	O
°	O
C	O
in	O
a	O
custom	O
-	O
made	O
aluminium	O
reaction	O
rack	O
with	O
a	O
re	O
-	O
usable	O
silicon	O
rubber	O
grid	O
placed	O
on	O
the	O
slides	O
to	O
form	O
75	O
separate	O
reaction	O
chambers	O
on	O
each	O
slide	O
[	O
24	O
]	O
.	O

The	O
hybridization	O
mixtures	O
,	O
containing	O
the	O
SBE	O
reaction	O
products	O
in	O
6.5	O
×	O
SSC	O
were	O
added	O
to	O
each	O
reaction	O
chamber	O
on	O
the	O
pre	O
-	O
heated	O
slide	O
.	O

The	O
hybridization	O
time	O
was	O
2.5	O
hours	O
at	O
42	O
°	O
C	O
followed	O
by	O
a	O
brief	O
rinse	O
with	O
4	O
×	O
SSC	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
the	O
slides	O
were	O
washed	O
twice	O
for	O
5	O
min	O
.	O

in	O
2	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
(	O
42	O
°	O
C	O
)	O
and	O
twice	O
for	O
1	O
min	O
.	O

in	O
0.2	O
×	O
SSC	O
(	O
room	O
temperature	O
)	O
.	O

Finally	O
,	O
the	O
slides	O
were	O
spin	O
dried	O
for	O
3	O
min	O
.	O

at	O
800	O
rpm	O
.	O

Signal	O
detection	O
The	O
signal	O
detection	O
was	O
performed	O
mainly	O
as	O
described	O
by	O
Lindroos	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescence	O
signals	O
were	O
detected	O
with	O
a	O
ScanArray	O
4000XL	O
instrument	O
and	O
the	O
ScanArray	O
Express	O
software	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

The	O
four	O
excitation	O
lasers	O
were	O
:	O
blue	O
Argon	O
,	O
488	O
nm	O
;	O
Green	O
HeNe	O
,	O
543.8	O
nm	O
;	O
Yellow	O
HeNe	O
,	O
594	O
nm	O
and	O
Red	O
HeNe	O
632.8	O
nm	O
.	O

The	O
laser	O
power	O
was	O
kept	O
constant	O
at	O
90	O
%	O
,	O
whereas	O
the	O
photo	O
-	O
multiplier	O
tube	O
(	O
PMT	O
)	O
varied	O
between	O
fluorophores	O
.	O

A	O
typical	O
setting	O
for	O
the	O
PMT	O
gain	O
was	O
65	O
,	O
75	O
,	O
65	O
and	O
70	O
%	O
for	O
the	O
fluorophores	O
Cy5-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
®	O
-5-ddATP	O
and	O
R110-ddGTP	O
,	O
respectively	O
.	O

Statistics	O
Association	O
tests	O
A	O
Bonferroni	O
corrected	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
the	O
genotypes	O
of	O
each	O
SNP	O
and	O
the	O
familiar	O
CRC	O
cohort	O
and	O
the	O
cohort	O
of	O
sporadic	O
CRC	O
,	O
respectively	O
.	O

Fifteen	O
tests	O
were	O
made	O
for	O
single	O
marker	O
associations	O
,	O
in	O
the	O
cohort	O
of	O
familiar	O
CRC	O
,	O
yielding	O
a	O
Bonferroni	O
corrected	O
significance	O
level	O
of	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Likewise	O
the	O
Bonferroni	O
corrected	O
p	O
-	O
value	O
of	O
the	O
cohort	O
of	O
sporadic	O
cases	O
was	O
0.05	O
/	O
13	O
=	O
0.0038	O
.	O

A	O
Bonferroni	O
corrected	O
Monte	O
Carlo	O
(	O
MC	O
)	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
each	O
pair	O
of	O
SNPs	O
,	O
and	O
sporadic	O
or	O
familiar	O
CRC	O
.	O

One	O
hundred	O
thousand	O
permutations	O
were	O
used	O
for	O
each	O
test	O
.	O

Missing	O
data	O
were	O
handled	O
by	O
omitting	O
persons	O
with	O
missing	O
data	O
in	O
the	O
genotype	O
counts	O
;	O
e.g.	O
all	O
individuals	O
with	O
missing	O
data	O
in	O
either	O
variant	O
i	O
d	O
26	O
or	O
variant	O
i	O
d	O
27	O
were	O
omitted	O
when	O
calculating	O
the	O
genotype	O
frequencies	O
of	O
that	O
specific	O
SNP	O
-	O
pair	O
.	O

Power	O
calculations	O

The	O
power	O
was	O
calculated	O
by	O
applying	O
the	O
Fisher	O
exact	O
test	O
to	O
10000	O
independent	O
simulated	O
cases	O
with	O
the	O
given	O
odds	O
ratio	O
and	O
frequency	O
of	O
the	O
disease	O
causing	O
genotype	O
.	O

In	O
that	O
case	O
the	O
power	O
is	O
the	O
proportion	O
of	O
the	O
simulations	O
that	O
reach	O
a	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Test	O
for	O
Hardy	O
-	O
Weinberg	O
proportions	O
Each	O
variant	O
was	O
tested	O
for	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
proportions	O
in	O
the	O
sub	O
-	O
cohort	O
,	O
using	O
the	O
exact	O
test	O
described	O
by	O
Wigginton	O
et	O
al.	O
[	O
25	O
]	O
.	O

The	O
used	O
significance	O
level	O
was	O
0.01	O
.	O

Linkage	O
disequilibrium	O
Linkage	O
disequilibrium	O
(	O
LD	O
)	O
was	O
investigated	O
using	O
HaploView	O
(	O
v.	O
3.31	O
)	O
,	O
[	O
26	O
]	O
and	O
genome	O
build	O
NCBI35	O
for	O
information	O
track	O
.	O

In	O
silico	O
analysis	O
In	O
silico	O
prediction	O
of	O
the	O
functional	O
consequence	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
SIFT	O
(	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
)	O
[	O
27	O
]	O
,	O
Polyphen	O
[	O
28	O
]	O
and	O
PMUT	O
[	O
29	O
]	O
.	O

Mis	O
-	O
splicing	O
was	O
analysed	O
using	O
SNAP	O
(	O
SNP	O
Annotation	O
Platform	O
)	O
[	O
30	O
]	O
.	O

The	O
alignments	O
of	O
MSH2	O
or	O
MLH1	O
polypeptides	O
used	O
in	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
ClustalW	O
[	O
31	O
]	O
.	O

Thirteen	O
variants	O
were	O
polymorphic	O
in	O
the	O
present	O
study	O
.	O

The	O
majority	O
of	O
the	O
polymorphic	O
variants	O
(	O
i.e.	O
9	O
/	O
13	O
)	O
were	O
silent	O
or	O
present	O
in	O
non	O
-	O
coding	O
regions	O
.	O

This	O
corresponds	O
with	O
common	O
variants	O
being	O
more	O
abundant	O
in	O
introns	O
and	O
other	O
regions	O
than	O
in	O
coding	O
regions	O
[	O
38	O
]	O
.	O

Three	O
of	O
polymorphic	O
variants	O
i.e.	O
MLH1	O
p.	O

Val219Ile	O
,	O
p.	O

Ser406Asn	O
and	O
p.	O

Lys618Ala	O
changed	O
non	O
-	O
conserved	O
amino	O
acids	O
and	O
one	O
i.e.	O
MSH2	O
pGly322Asp	O
changed	O
a	O
conserved	O
amino	O
acid	O
.	O

Furthermore	O
,	O
two	O
polymorphic	O
variants	O
i.e.hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
demonstrated	O
borderline	O
significant	O
p	O
-	O
values	O
i.e.	O
0.0037	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
13	O
=	O
0.0038	O
)	O
and	O
0.0044	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
15	O
=	O
0.0033	O
)	O
,	O
respectively	O
.	O

It	O
has	O
been	O
stated	O
that	O
the	O
conventional	O
threshold	O
for	O
declaration	O
of	O
statistical	O
evidence	O
of	O
association	O
(	O
i.e.	O
a	O
p	O
-	O
value	O
of	O
5	O
×	O
10	O
-	O
2	O
)	O
is	O
not	O
sufficient	O
to	O
detect	O
gene	O
-	O
disease	O
interactions	O
.	O

Consequently	O
,	O
it	O
has	O
been	O
suggested	O
to	O
lower	O
the	O
threshold	O
to	O
5	O
×	O
10	O
-	O
5	O
[	O
39	O
]	O
.	O

The	O
borderline	O
significant	O
p	O
-	O
values	O
and	O
the	O
previously	O
published	O
functional	O
analysis	O
of	O
one	O
of	O
the	O
variants	O
suggest	O
that	O
hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
are	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
neither	O
sporadic	O
nor	O
familiar	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
polymorphic	O
variants	O
were	O
not	O
associated	O
with	O
CRC	O
in	O
the	O
analyzed	O
cohorts	O
,	O
neither	O
individually	O
nor	O
as	O
pairs	O
,	O
and	O
they	O
are	O
hence	O
neutral	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

Some	O
of	O
these	O
variants	O
i.e.	O
hMLH1	O
c.655	O
A	O
>	O
G	O
(	O
p	O
.	O
Val219Ile	O
)	O
,	O
c.1217G	O
>	O
A	O
(	O
p.	O

Ser406Asn	O
)	O
,	O
c.1558	O
+	O
14	O
G	O
>	O
A	O
and	O
hMSH2	O
c.1959G	O
>	O
T	O
(	O
p.	O

Leu653Leu	O
)	O
have	O
been	O
characterized	O
as	O
neutral	O
variants	O
in	O
other	O
studies	O
as	O
well	O
[	O
40	O
-	O
42	O
]	O
.	O

In	O
vitro	O
functional	O
analysis	O
have	O
also	O
demonstrated	O
that	O
the	O
variants	O
MLH1	O
p.	O

Val219Ile	O
and	O
p.	O

Ser406Asn	O
exhibit	O
wild	O
-	O
type	O
activity	O
[	O
8,11,12	O
]	O
.	O

The	O
hMSH2	O
variant	O
c.965G	O
>	O
A	O
(	O
p.	O

Gly322Asp	O
)	O
has	O
previously	O
been	O
classified	O
as	O
a	O
neutral	O
variant	O
[	O
43	O
]	O
.	O

This	O
variant	O
changes	O
a	O
conserved	O
amino	O
acid	O
and	O
functional	O
analysis	O
in	O
yeast	O
has	O
shown	O
that	O
it	O
has	O
a	O
slightly	O
reduced	O
MMR	O
activity	O
[	O
8,44	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
frequency	O
of	O
the	O
c.965	O
G	O
>	O
A	O
variant	O
was	O
higher	O
in	O
the	O
cohort	O
of	O
individuals	O
with	O
familiar	O
CRC	O
compared	O
to	O
the	O
sub	O
-	O
cohort	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
Tables	O
3	O
and	O
4	O
)	O
.	O

Results	O
regarding	O
the	O
MLH1	O
p.	O

Lys618Ala	O
variants	O
have	O
so	O
far	O
been	O
contradictory	O
.	O

Functional	O
analyses	O
have	O
identified	O
this	O
variant	O
both	O
as	O
a	O
pathogenic	O
mutation	O
and	O
as	O
a	O
neutral	O
variant	O
[	O
9,11,45	O
-	O
47	O
]	O
.	O

Raevaara	O
et	O
al.	O
used	O
four	O
different	O
assays	O
to	O
evaluate	O
the	O
pathogenic	O
status	O
[	O
9	O
]	O
.	O

In	O
all	O
four	O
assays	O
the	O
p.	O

Lys618Val	O
variant	O
functioned	O
like	O
wt	O
MLH1	O
.	O

In	O
addition	O
,	O
p.	O

Lys618Ala	O
has	O
been	O
identified	O
in	O
one	O
healthy	O
control	O
in	O
a	O
previous	O
study	O
[	O
48	O
]	O
.	O

The	O
identification	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
in	O
controls	O
in	O
the	O
present	O
study	O
further	O
support	O
,	O
that	O
this	O
variant	O
is	O
not	O
a	O
disease	O
causing	O
mutation	O
involved	O
in	O
HNPCC	O
or	O
HNPCC	O
-	O
related	O
cancers	O
.	O

In	O
addition	O
,	O
the	O
frequencies	O
of	O
the	O
variant	O
in	O
the	O
cohorts	O
analyzed	O
in	O
the	O
present	O
study	O
did	O
not	O
differ	O
significantly	O
and	O
therefore	O
p.	O

Lys618Ala	O
does	O
not	O
increase	O
susceptibility	O
to	O
sporadic	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

In	O
conclusion	O
none	O
of	O
the	O
polymorphic	O
variants	O
in	O
the	O
present	O
study	O
are	O
highly	O
associated	O
with	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

When	O
we	O
ran	O
null	O
simulations	O
in	O
the	O
presence	O
of	O
heterogeneity	O
of	O
marker	O
alleles	O
,	O
disease	O
alleles	O
,	O
or	O
both	O
,	O
we	O
observed	O
that	O
Zc	O
and	O
Zp	O
behaved	O
differently	O
depending	O
on	O
the	O
heterogeneity	O
model	O
we	O
simulated	O
.	O

Although	O
Zp	O
was	O
conservatively	O
biased	O
when	O
disease	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
marker	O
allele	O
frequencies	O
differed	O
,	O
its	O
small	O
conservative	O
bias	O
was	O
not	O
significantly	O
different	O
from	O
that	O
observed	O
in	O
the	O
homogeneous	O
population	O
of	O
Table	O
2	O
.	O

In	O
contrast	O
,	O
Zc	O
exhibited	O
an	O
anticonservative	O
bias	O
when	O
marker	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
disease	O
allele	O
frequencies	O
differed	O
.	O

Alternative	O
Model	O
Simulation	O
Results	O
A	O
subset	O
of	O
results	O
from	O
alternative	O
model	O
simulations	O
in	O
which	O
there	O
were	O
linkages	O
are	O
given	O
in	O
Table	O
4	O
,	O
based	O
on	O
20	O
replicate	O
simulations	O
for	O
each	O
combination	O
of	O
parameters	O
.	O

The	O
numbers	O
given	O
represent	O
mean	O
Z	O
statistics	O
,	O
their	O
ARE	O
values	O
,	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

The	O
results	O
displayed	O
were	O
chosen	O
to	O
highlight	O
the	O
effect	O
of	O
sampling	O
(	O
and	O
genotyping	O
)	O
varying	O
the	O
numbers	O
of	O
unaffected	O
sibs	O
and/or	O
parents	O
from	O
families	O
with	O
two	O
or	O
three	O
affected	O
sibs	O
and	O
two	O
unaffected	O
sibs	O
.	O

Full	O
results	O
are	O
available	O
online	O
[	O
64	O
]	O
.	O

On	O
average	O
,	O
the	O
concordant	O
test	O
was	O
always	O
more	O
efficient	O
on	O
a	O
per	O
-	O
genotype	O
basis	O
than	O
the	O
paired	O
test	O
,	O
although	O
the	O
power	O
of	O
the	O
paired	O
test	O
was	O
usually	O
greater	O
when	O
the	O
number	O
of	O
unaffected	O
sibs	O
tested	O
was	O
>	O
2	O
.	O

Alternative	O
Model	O
Simulation	O
Mean	O
Z	O
score	O
,	O
asymptotic	O
relative	O
efficiency	O
per	O
genotype	O
(	O
ARE	O
–	O
see	O
text	O
)	O
,	O
and	O
sample	O
size	O
required	O
to	O
attain	O
80	O
%	O
power	O
for	O
two	O
-	O
point	O
linkage	O
(	O
θ	O
=	O
0.05	O
)	O
for	O
predisposition	O
to	O
colorectal	O
cancer	O
with	O
a	O
baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
under	O
3	O
different	O
heterogeneity	O
models	O
:	O
A	O
)	O
no	O
heterogeneity	O
;	O
B	O
)	O
an	O
equally	O
penetrant	O
,	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
unlinked	O
predisposing	O
locus	O
;	O
C	O
)	O
an	O
equally	O
penetrant	O
,	O
equally	O
common	O
unlinked	O
predisposing	O
locus	O
.	O

All	O
results	O
based	O
on	O
500	O
simulated	O
families	O
and	O
20	O
replicate	O
simulations	O
per	O
parameter	O
set	O
.	O

Zc	O
mean	O
concordant	O
test	O
;	O

Zp	O
mean	O
paired	O
test	O
;	O
ARE	O
(	O
Zc	O
)	O
asymptotic	O
relative	O
efficiency	O
concordant	O
test	O
;	O
ARE	O
(	O
Zp	O
)	O
asymptotic	O
relative	O
efficiency	O
paired	O
test	O
;	O
Nc	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
concordant	O
test	O
;	O
Np	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
paired	O
test	O
.	O

Regression	O
Models	O
Table	O
5	O
shows	O
the	O
effect	O
of	O
various	O
design	O
and	O
population	O
parameters	O
on	O
the	O
noncentrality	O
parameter	O
for	O
both	O
the	O
concordant	O
-	O
only	O
test	O
(	O
Zc	O
/	O
F	O
)	O
and	O
the	O
paired	O
test	O
(	O
Zp	O
/	O
F	O
)	O
.	O

The	O
only	O
change	O
in	O
parameterization	O
of	O
the	O
model	O
for	O
the	O
paired	O
test	O
vis	O
-	O
a	O
-	O
vis	O
the	O
concordant	O
test	O
involved	O
substituting	O
the	O
number	O
of	O
typed	O
unaffected	O
sibs	O
for	O
the	O
total	O
number	O
of	O
unaffected	O
sibs	O
.	O

The	O
AR	O
for	O
the	O
linked	O
locus	O
had	O
the	O
largest	O
positive	O
effect	O
on	O
power	O
of	O
the	O
concordant	O
test	O
,	O
followed	O
closely	O
by	O
the	O
negative	O
effect	O
on	O
power	O
of	O
increasing	O
AR	O
at	O
the	O
unlinked	O
locus	O
and	O
increasing	O
recombination	O
fraction	O
between	O
the	O
marker	O
and	O
trait	O
loci	O
.	O

Increasing	O
the	O
number	O
of	O
affected	O
sibs	O
per	O
family	O
and	O
increasing	O
the	O
number	O
of	O
affected	O
sibs	O
genotyped	O
per	O
family	O
both	O
substantially	O
improved	O
power	O
.	O

The	O
number	O
of	O
unaffected	O
sibs	O
present	O
in	O
sampled	O
families	O
had	O
little	O
or	O
no	O
effect	O
on	O
power	O
.	O

Increased	O
power	O
was	O
also	O
observed	O
for	O
increasing	O
numbers	O
of	O
available	O
parents	O
,	O
the	O
size	O
of	O
the	O
effect	O
on	O
Zc	O
/	O
F	O
being	O
about	O
15	O
%	O
of	O
the	O
effect	O
of	O
increasing	O
numbers	O
of	O
affected	O
sibs	O
.	O

Substituting	O
spouse	O
and	O
offspring	O
for	O
an	O
unavailable	O
affected	O
sib	O
reduced	O
power	O
substantially	O
,	O
but	O
genotyping	O
a	O
second	O
child	O
recovered	O
much	O
of	O
that	O
lost	O
power	O
.	O

Comparison	O
of	O
two	O
-	O
point	O
vs.	O
multipoint	O
linkage	O
scores	O
under	O
various	O
non	O
-	O
null	O
simulation	O
conditions	O
.	O

All	O
simulations	O
employed	O
20	O
replicates	O
of	O
500	O
families	O
with	O
2	O
affected	O
and	O
2	O
unaffected	O
sibs	O
,	O
all	O
sibs	O
typed	O
,	O
no	O
parents	O
or	O
children	O
typed	O
.	O

a	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
no	O
genetic	O
heterogeneity	O
.	O

b	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
and	O
a	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
,	O
equally	O
penetrant	O
unlinked	O
predisposition	O
syndrome	O
.	O

c	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.00325	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.002	O
.	O

d	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.0035	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.001	O
.	O

Replacement	O
of	O
a	O
missing	O
affected	O
individual	O
by	O
a	O
spouse	O
and	O
offspring	O
is	O
not	O
generally	O
as	O
efficient	O
per	O
genotype	O
as	O
if	O
that	O
individual	O
had	O
been	O
available	O
,	O
although	O
the	O
efficiency	O
improves	O
with	O
each	O
additional	O
offspring	O
included	O
.	O

Figure	O
5	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
ASP	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Figure	O
6	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
affected	O
sib	O
trio	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Because	O
families	O
with	O
three	O
affected	O
sibs	O
are	O
more	O
likely	O
to	O
be	O
segregating	O
a	O
disease	O
-	O
predisposing	O
allele	O
than	O
families	O
with	O
two	O
affected	O
sibs	O
,	O
each	O
family	O
is	O
more	O
informative	O
for	O
linkage	O
,	O
even	O
if	O
DNA	O
is	O
available	O
for	O
only	O
two	O
sibs	O
.	O

Substituting	O
the	O
spouse	O
and	O
one	O
or	O
more	O
offspring	O
for	O
the	O
missing	O
sib	O
adds	O
additional	O
power	O
,	O
although	O
at	O
the	O
cost	O
of	O
additional	O
genotyping	O
.	O

Conclusion	O
We	O
have	O
shown	O
that	O
for	O
a	O
wide	O
variety	O
of	O
situations	O
relevant	O
to	O
sib	O
-	O
pair	O
studies	O
of	O
colon	O
cancer	O
and	O
similar	O
late	O
-	O
onset	O
complex	O
diseases	O
,	O
standard	O
concordant	O
-	O
pair	O
allele	O
-	O
sharing	O
statistics	O
based	O
on	O
identity	O
by	O
descent	O
probabilities	O
are	O
more	O
efficient	O
than	O
similarly	O
constructed	O
discordant	O
statistics	O
in	O
homogeneous	O
populations	O
,	O
but	O
may	O
be	O
biased	O
away	O
from	O
the	O
null	O
in	O
situations	O
where	O
subjects	O
are	O
chosen	O
from	O
multiple	O
populations	O
having	O
differing	O
marker	O
allele	O
frequencies	O
or	O
other	O
sources	O
of	O
bias	O
.	O

Where	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
is	O
anticipated	O
because	O
of	O
underlying	O
population	O
admixture	O
,	O
linkage	O
tests	O
based	O
on	O
comparison	O
of	O
concordant	O
vs.	O
discordant	O
allele	O
sharing	O
should	O
be	O
considered	O
.	O

Either	O
of	O
these	O
approaches	O
should	O
allow	O
studies	O
of	O
500–1000	O
families	O
containing	O
an	O
ASP	O
to	O
achieve	O
reasonable	O
power	O
to	O
detect	O
linkage	O
under	O
conditions	O
including	O
genetic	O
and	O
population	O
heterogeneity	O
,	O
unavailable	O
parents	O
,	O
misspecified	O
allele	O
frequencies	O
,	O
and	O
other	O
afflictions	O
of	O
the	O
sib	O
-	O
pair	O
design	O
.	O

While	O
collecting	O
DNA	O
samples	O
from	O
unaffected	O
sibs	O
can	O
be	O
useful	O
for	O
a	O
wide	O
variety	O
of	O
purposes	O
–	O
especially	O
if	O
multipoint	O
methods	O
are	O
used	O
–	O
in	O
many	O
circumstances	O
it	O
should	O
be	O
unnecessary	O
to	O
genotype	O
these	O
samples	O
for	O
purposes	O
of	O
performing	O
a	O
genome	O
scan	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
and	O
microsatellites	O
are	O
being	O
used	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
a	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	O
and	O
unaffected	O
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

For	O
dense	O
SNP	O
mapping	O
studies	O
,	O
analysis	O
using	O
individual	O
SNPs	O
will	O
not	O
be	O
sufficiently	O
informative	O
and	O
so	O
multipoint	O
analyses	O
will	O
be	O
required	O
,	O
but	O
unless	O
the	O
parents	O
are	O
all	O
available	O
,	O
analyses	O
should	O
be	O
restricted	O
to	O
markers	O
that	O
show	O
low	O
levels	O
of	O
linkage	O
disequilibrium	O
(	O
the	O
reference	O
here	O
would	O
be	O
to	O
a	O
paper	O
by	O
Bacanu	O
SA	O
.	O

Multipoint	O
linkage	O
analysis	O
for	O
a	O
very	O
dense	O
set	O
of	O
markers	O
Genet	O
Epidemiol	O
.	O

2005	O
Nov;29	O
(	O
3	O
)	O
:195–203	O
.	O
)	O
or	O
estimate	O
haplotype	O
frequencies	O
(	O
Abecasis	O
and	O
Wigginton	O
,	O
Handling	O
marker	O
-	O
marker	O
linkage	O
disequilibrium	O
:	O
pedigree	O
analysis	O
with	O
clustered	O
markers	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2005	O
Nov;77	O
(	O
5	O
)	O
:754–67	O
.	O

Epub	O
2005	O
Sep	O
20	O
.	O
)	O

If	O
the	O
parents	O
are	O
available	O
,	O
even	O
though	O
we	O
have	O
shown	O
that	O
genotyping	O
them	O
is	O
inefficient	O
,	O
an	O
argument	O
can	O
be	O
made	O
for	O
genotyping	O
them	O
because	O
their	O
inclusion	O
ameliorates	O
any	O
potential	O
effect	O
of	O
population	O
admixture	O
,	O
greatly	O
facilitates	O
the	O
identification	O
of	O
any	O
genotyping	O
errors	O
and	O
reduces	O
the	O
dependence	O
upon	O
correct	O
specification	O
of	O
haplotype	O
frequencies	O
when	O
multipoint	O
analyses	O
are	O
conducted	O
(	O
can	O
refer	O
to	O
Huang	O
et	O
al	O
,	O
2004	O
Ignoring	O
linkage	O
disequilibrium	O
among	O
tightly	O
linked	O
markers	O
induces	O
false	O
-	O
positive	O
evidence	O
of	O
linkage	O
for	O
affected	O
sib	O
pair	O
analysis	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2004	O
Dec;75	O
(	O
6	O
)	O
:1106	O
-	O
12	O
.	O

Epub	O
2004	O
Oct	O
18	O
.	O
)	O
.	O

The	O
choice	O
of	O
whether	O
or	O
not	O
to	O
genotype	O
unaffected	O
individuals	O
also	O
would	O
depend	O
upon	O
the	O
feasibility	O
and	O
cost	O
of	O
cherry	O
-	O
picking	O
for	O
regional	O
genotyping	O
of	O
regions	O
showing	O
evidence	O
for	O
linkage	O
,	O
but	O
we	O
have	O
not	O
studied	O
either	O
of	O
these	O
issues	O
in	O
this	O
paper	O
.	O

Admixture	O
is	O
more	O
likely	O
to	O
be	O
of	O
concern	O
when	O
studying	O
populations	O
that	O
are	O
known	O
to	O
have	O
been	O
founded	O
by	O
different	O
ethnic	O
groups	O
or	O
races	O
such	O
as	O
Hispanics	O
and	O
African	O
-	O
Americans	O
.	O

INTRODUCTION	O
Colorectal	O
cancer	O
arises	O
from	O
a	O
series	O
of	O
somatically	O
inherited	O
changes	O
,	O
including	O
mutations	O
and	O
transmissible	O
epigenetic	O
events	O
such	O
as	O
methylation	O
of	O
CpG	O
islands	O
(	O
1	O
)	O
,	O
some	O
or	O
all	O
of	O
which	O
produce	O
a	O
growth	O
advantage	O
relative	O
to	O
surrounding	O
cells	O
(	O
2	O
,	O
3	O
)	O
.	O

Among	O
the	O
epigenetic	O
events	O
involved	O
in	O
tumorigenesis	O
are	O
DNA	O
methylation	O
,	O
genomic	O
imprinting	O
,	O
and	O
histone	O
modification	O
(	O
4	O
)	O
.	O

Global	O
decreases	O
in	O
5-methylcytosine	O
content	O
have	O
been	O
associated	O
with	O
tumor	O
formation	O
,	O
including	O
that	O
of	O
colorectal	O
cancers	O
.	O

Another	O
molecular	O
defect	O
commonly	O
occurring	O
during	O
neoplasia	O
is	O
de	O
novo	O
CpG	O
island	O
methylation	O
(	O
4	O
-	O
6	O
)	O
.	O

Recently	O
,	O
a	O
distinct	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
was	O
described	O
,	O
termed	O
the	O
CpG	O
island	O
methylation	O
phenotype	O
(	O
CIMP	O
)	O
(	O
7	O
)	O
.	O

This	O
pathway	O
was	O
uncovered	O
through	O
a	O
series	O
of	O
observations	O
that	O
included	O
association	O
between	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
hypermethylation	O
of	O
multiple	O
genes	O
,	O
from	O
the	O
concordance	O
between	O
the	O
methylation	O
status	O
of	O
different	O
genes	O
unrelated	O
to	O
the	O
gene	O
function	O
or	O
chromosomal	O
location	O
,	O
and	O
from	O
the	O
bimodal	O
distribution	O
of	O
methylation	O
in	O
a	O
selected	O
subset	O
of	O
genes	O
.	O

Colorectal	O
cancer	O
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	O
-	O
related	O
deaths	O
worldwide	O
(	O
8)	O
.	O

Almost	O
70	O
%	O
of	O
all	O
colorectal	O
cancers	O
are	O
sporadic	O
.	O

Of	O
the	O
remaining	O
30	O
%	O
,	O
a	O
small	O
number	O
belong	O
to	O
the	O
familial	O
syndromes	O
of	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
and	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
,	O
whereas	O
the	O
vast	O
majority	O
show	O
non	O
-	O
syndromatic	O
familial	O
susceptibility	O
(	O
9	O
)	O
.	O

The	O
proportion	O
of	O
all	O
cases	O
considered	O
familial	O
depends	O
in	O
the	O
definition	O
.	O

Of	O
all	O
patients	O
with	O
colorectal	O
cancer	O
,	O
11	O
-	O
16	O
%	O
have	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
with	O
colorectal	O
cancer	O
(	O
10	O
,	O
11	O
)	O
,	O
but	O
the	O
proportion	O
is	O
much	O
higher	O
if	O
second-	O
or	O
third	O
-	O
degree	O
relatives	O
are	O
considered	O
.	O

In	O
one	O
study	O
,	O
53	O
%	O
of	O
colorectal	O
cancer	O
probands	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
cancer	O
(	O
11	O
)	O
.	O

In	O
fact	O
,	O
first	O
-	O
degree	O
relatives	O
of	O
patients	O
affected	O
by	O
colorectal	O
cancer	O
,	O
but	O
who	O
do	O
not	O
fulfill	O
the	O
criteria	O
for	O
FAP	O
and	O
HNPCC	O
,	O
have	O
a	O
more	O
than	O
2-fold	O
increased	O
risk	O
of	O
developing	O
tumors	O
of	O
the	O
large	O
intestine	O
(	O
12	O
)	O
.	O

HNPCC	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
the	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
hMLH1	O
,	O
hMSH2	O
,	O
hMSH6	O
,	O
and	O
hPMS2	O
,	O
with	O
a	O
penetrance	O
of	O
approximately	O
80	O
%	O
for	O
colorectal	O
cancer	O
,	O
60	O
%	O
for	O
endometrial	O
cancer	O
,	O
and	O
below	O
20	O
%	O
for	O
other	O
cancers	O
(	O
13	O
)	O
.	O

HNPCC	O
is	O
characterized	O
by	O
early	O
onset	O
,	O
the	O
development	O
of	O
neoplastic	O
lesions	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
and	O
MSI	O
.	O

The	O
Amsterdam	O
criteria	O
for	O
HNPCC	O
are	O
strictly	O
defined	O
and	O
exclude	O
most	O
tumors	O
suspected	O
of	O
being	O
hereditary	O
.	O

In	O
contrast	O
,	O
the	O
Bethesda	O
guidelines	O
broaden	O
the	O
disease	O
spectrum	O
by	O
including	O
colorectal	O
cancer	O
families	O
with	O
specific	O
accompanying	O
cancers	O
and	O
clinicopathologic	O
characteristics	O
(	O
13	O
,	O
14	O
)	O
.	O

These	O
latter	O
criteria	O
provide	O
important	O
clues	O
for	O
identifying	O
genetic	O
pathways	O
associated	O
with	O
atypical	O
phenotypes	O
of	O
hereditary	O
colorectal	O
cancer	O
.	O

Although	O
the	O
strict	O
Amsterdam	O
criteria	O
could	O
be	O
used	O
to	O
detect	O
underlying	O
molecular	O
events	O
in	O
hereditary	O
colorectal	O
cancers	O
,	O
only	O
50	O
%	O
(	O
range	O
,	O
30	O
-	O
80	O
%	O
)	O
of	O
cases	O
involve	O
a	O
detectable	O
germline	O
mutation	O
in	O
an	O
MMR	O
gene	O
(	O
15	O
)	O
.	O

Therefore	O
,	O
by	O
restricting	O
the	O
definition	O
of	O
HNPCC	O
to	O
tumors	O
containing	O
an	O
MMR	O
germline	O
mutation	O
,	O
only	O
about	O
2.5	O
%	O
of	O
colorectal	O
cancers	O
are	O
thought	O
to	O
be	O
caused	O
by	O
HNPCC	O
.	O

Thus	O
,	O
the	O
carcinogenesis	O
pathways	O
and	O
molecular	O
events	O
in	O
familial	O
cancers	O
with	O
no	O
detectable	O
germline	O
mutations	O
and/or	O
not	O
fulfilling	O
HNPCC	O
criteria	O
,	O
remain	O
to	O
be	O
determined	O
.	O

Grouping	O
of	O
adenomas	O
and	O
carcinomas	O
by	O
promoter	O
methylation	O
status	O
Tumors	O
were	O
classified	O
as	O
methylation	O
-	O
resistant	O
(	O
MR	O
)	O
if	O
fewer	O
than	O
two	O
loci	O
were	O
methylated	O
or	O
methylation	O
-	O
prone	O
(	O
MP	O
)	O
if	O
two	O
or	O
more	O
loci	O
were	O
methylated	O
.	O

Each	O
tumor	O
and	O
group	O
were	O
represented	O
by	O
a	O
methylation	O
index	O
(	O
number	O
of	O
loci	O
methylated	O
/	O
number	O
of	O
loci	O
evaluated	O
)	O
.	O

MSI	O
MSI	O
status	O
was	O
determined	O
by	O
PCR	O
using	O
primers	O
to	O
amplify	O
the	O
five	O
microsatellite	O
markers	O
recommended	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
Bethesda	O
,	O
MD	O
.	O
,	O
U.S.A.	O
)	O
,	O
i.e.	O
,	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
,	O
and	O
D2S123	O
(	O
13	O
)	O
.	O

Denaturation	O
of	O
the	O
PCR	O
products	O
,	O
gel	O
electrophoresis	O
,	O
and	O
silver	O
staining	O
were	O
performed	O
as	O
described	O
.	O

MSI	O
was	O
scored	O
as	O
positive	O
when	O
there	O
was	O
a	O
definite	O
shift	O
of	O
PCR	O
product	O
in	O
tumor	O
DNA	O
compared	O
with	O
normal	O
mucosal	O
DNA	O
.	O

All	O
MSI	O
-	O
positive	O
loci	O
were	O
confirmed	O
on	O
duplicate	O
examinations	O
.	O

Tumors	O
with	O
MSI	O
in	O
at	O
least	O
two	O
loci	O
were	O
classified	O
as	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
,	O
tumors	O
with	O
MSI	O
at	O
one	O
locus	O
were	O
classified	O
as	O
low	O
frequency	O
MSI	O
(	O
MSI	O
-	O
L	O
)	O
,	O
and	O
tumors	O
with	O
MSI	O
at	O
no	O
locus	O
were	O
classified	O
as	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
.	O

Statistical	O
analysis	O
The	O
interactions	O
between	O
methylation	O
and	O
clinicopathologic	O
parameters	O
in	O
two	O
groups	O
were	O
evaluated	O
with	O
chi	O
-	O
square	O
tests	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O

All	O
p	O
values	O
were	O
two	O
-	O
sided	O
,	O
and	O
a	O
p	O
value	O
less	O
than	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
SPSS	O
program	O
(	O
Version	O
12.0	O
,	O
Chicago	O
,	O
IL	O
,	O
U.S.A.	O
)	O
.	O

The	O
majority	O
of	O
tumors	O
were	O
found	O
to	O
be	O
moderately	O
differentiated	O
in	O
African	O
Americans	O
(	O
79	O
%	O
)	O
and	O
Omanis	O
(	O
82	O
%	O
;	O
Table	O
1	O
,	O
2	O
)	O
.	O

Iranian	O
tumors	O
were	O
mostly	O
well	O
differentiated	O
(	O
54	O
%	O
)	O
.	O

The	O
percentage	O
of	O
moderately	O
differentiated	O
tumors	O
was	O
86	O
%	O
in	O
the	O
MSI	O
-	O
H	O
Omani	O
group	O
compared	O
with	O
72	O
%	O
in	O
African	O
Americans	O
and	O
64	O
%	O
in	O
Iranians	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
seven	O
and	O
one	O
MSI	O
-	O
H	O
tumors	O
showed	O
poor	O
differentiation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
.	O

While	O
in	O
African	O
Americans	O
,	O
one	O
MSI	O
-	O
H	O
was	O
well	O
differentiated	O
,	O
no	O
patient	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
cases	O
was	O
poorly	O
differentiated	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

The	O
difference	O
was	O
insignificant	O
trend	O
in	O
African	O
Americans	O
and	O
Omanis	O
but	O
in	O
Iranian	O
patients	O
differentiation	O
was	O
significantly	O
correlated	O
with	O
MSI	O
-	O
H	O
occurrence	O
.	O

This	O
finding	O
was	O
not	O
sustained	O
in	O
multivariate	O
analysis	O
.	O

Most	O
of	O
the	O
patients	O
in	O
the	O
series	O
were	O
stage	O
II	O
or	O
higher	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
,	O
with	O
45	O
%	O
[	O
13	O
]	O
of	O
African	O
American	O
,	O
62	O
%	O
[	O
5	O
]	O
of	O
Omani	O
,	O
and	O
14	O
%	O
[	O
2	O
]	O
of	O
Iranian	O
MSI	O
-	O
H	O
lesions	O
at	O
stage	O
II	O
.	O

Thirty	O
-	O
eight	O
percent	O
[	O
24	O
]	O
of	O
African	O
American	O
,	O
28	O
%	O
[	O
15	O
]	O
of	O
Omani	O
,	O
and	O
23	O
%	O
[	O
12	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
II	O
(	O
Table	O
3	O
)	O
.	O

Forty	O
-	O
one	O
percent	O
[	O
12	O
]	O
of	O
African	O
American	O
,	O
25	O
%	O
[	O
2	O
]	O
of	O
Omani	O
,	O
and	O
79	O
%	O
[	O
11	O
]	O
of	O
Iranian	O
of	O
the	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

Thirty	O
-	O
seven	O
percent	O
[	O
23	O
]	O
of	O
African	O
American	O
,	O
55	O
%	O
[	O
29	O
]	O
of	O
Omani	O
,	O
and	O
67	O
%	O
[	O
26	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
.	O

Fourteen	O
percent	O
[	O
9	O
]	O
of	O
African	O
American	O
,	O
15	O
%	O
[	O
8	O
]	O
of	O
Omani	O
,	O
and	O
7	O
%	O
[	O
3	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
IV	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

There	O
was	O
insignificant	O
trend	O
in	O
the	O
stage	O
of	O
the	O
lesions	O
between	O
the	O
MSI	O
and	O
non	O
-	O
MSI	O
-	O
H	O
groups	O
.	O

Correlation	O
between	O
methylation	O
pattern	O
of	O
the	O
hMLH1	O
promoter	O
and	O
MSI	O
status	O
Among	O
MSI	O
-	O
H	O
samples	O
,	O
hMLH1	O
promoter	O
methylation	O
was	O
found	O
in	O
90	O
%	O
[	O
18	O
]	O
of	O
African	O
American	O
,	O
75	O
%	O
[	O
6	O
]	O
of	O
Omani	O
and	O
71	O
%	O
[	O
10	O
]	O
of	O
Iranian	O
tumors	O
,	O
confirming	O
a	O
previous	O
finding	O
of	O
predominant	O
methylation	O
of	O
these	O
genes	O
of	O
the	O
promoter	O
in	O
Africans	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
[	O
3,4	O
]	O
.	O

Non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
both	O
African	O
Americans	O
and	O
Omani	O
tumors	O
showed	O
methylation	O
of	O
the	O
hMLH1	O
promoter	O
as	O
well	O
(	O
>	O
80	O
%	O
)	O
.	O

In	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
patients	O
,	O
the	O
frequency	O
of	O
hMLH1	O
methylation	O
was	O
3	O
%	O
[	O
1	O
]	O
.	O

The	O
methylation	O
status	O
of	O
hMLH1	O
does	O
not	O
seem	O
to	O
be	O
gender-	O
or	O
stage	O
-	O
specific	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	O
methylation	O
has	O
a	O
significant	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
13.84	O
(	O
1.05–182.72	O
)	O
;	O
p	O
=	O
0.046	O
)	O
(	O
Table	O
4	O
)	O
.	O

In	O
MSI	O
-	O
H	O
tumors	O
,	O
p16	O
methylation	O
occurred	O
in	O
33	O
%	O
[	O
7	O
]	O
of	O
African	O
American	O
,	O
12	O
%	O
[	O
1	O
]	O
of	O
Omani	O
and	O
50	O
%	O
[	O
7	O
]	O
of	O
Iranian	O
tumors	O
.	O

While	O
it	O
was	O
more	O
than	O
40	O
%	O
in	O
non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
African	O
Americans	O
and	O
Omani	O
patient	O
populations	O
,	O
this	O
figure	O
was	O
3	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
CRC	O
patients	O
.	O

Methods	O
We	O
analyzed	O
40	O
HNPCC	O
patients	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
with	O
histological	O
verified	O
colorectal	O
carcinoma	O
and	O
a	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	O
patients	O
with	O
no	O
familial	O
predisposition	O
,	O
observed	O
and	O
treated	O
at	O
the	O
Regina	O
Elena	O
Cancer	O
Institute	O
of	O
Rome	O
during	O
the	O
period	O
1970–1993	O
[	O
23	O
]	O
.	O

HNPCC	O
patients	O
were	O
selected	O
by	O
both	O
personal	O
and	O
familial	O
history	O
(	O
performing	O
complete	O
pedigree	O
including	O
first	O
and	O
second	O
-	O
degree	O
relatives	O
)	O
according	O
to	O
Amsterdam	O
I	O
criteria	O
.	O

In	O
15	O
patients	O
of	O
the	O
HNPCC	O
group	O
,	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	O
instability	O
,	O
investigating	O
mutations	O
in	O
mismatch	O
repair	O
genes	O
as	O
hMLH1	O
and	O
hMSH2	O
correlated	O
with	O
disease	O
.	O

We	O
analyzed	O
seven	O
microsatellite	O
loci	O
:	O
D2S123	O
,	O
D3S1611	O
,	O
and	O
BAT-26	O
,	O
D9S145	O
,	O
D1S158	O
,	O
SCZD1	O
,	O
and	O
D11S905	O
[	O
5,14,24,25	O
]	O
.	O

All	O
cases	O
were	O
pathologically	O
staged	O
taking	O
into	O
account	O
a	O
total	O
number	O
of	O
lymphonodes	O
exceeding	O
7	O
(	O
range	O
7	O
to	O
31	O
,	O
mean	O
13.0	O
,	O
mode	O
11.9	O
,	O
standard	O
deviation	O
6.2	O
)	O
,	O
as	O
recommended	O
by	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
/	O
International	O
Union	O
Against	O
Cancer	O
[	O
26	O
]	O
.	O

Histological	O
examination	O
was	O
performed	O
according	O
to	O
WHO	O
criteria	O
and	O
carcinomas	O
were	O
classified	O
according	O
to	O
the	O
Dukes	O
'	O
stage	O
.	O

Furthermore	O
,	O
we	O
defined	O
the	O
right	O
colon	O
as	O
the	O
tract	O
from	O
the	O
cecum	O
to	O
the	O
splenic	O
flexure	O
.	O

The	O
left	O
colon	O
included	O
the	O
descending	O
and	O
sigmoid	O
colon	O
.	O

The	O
rectum	O
was	O
defined	O
as	O
the	O
rectosigmoid	O
junction	O
and	O
rectum	O
.	O

From	O
1990	O
,	O
the	O
rectal	O
cancer	O
patients	O
clinically	O
staged	O
Dukes	O
'	O
B	O
and	O
C	O
were	O
addressed	O
to	O
high	O
-	O
dose	O
pelvic	O
radiotherapy	O
,	O
all	O
the	O
rectal	O
cancer	O
patients	O
underwent	O
a	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
surgery	O
.	O

Adjuvant	O
i.v	O
.	O

chemotherapy	O
was	O
administered	O
in	O
all	O
the	O
eligible	O
Dukes	O
'	O
C	O
colorectal	O
cancer	O
patients	O
,	O
those	O
staged	O
Dukes	O
'	O
D	O
underwent	O
chemotherapy	O
.	O

Patients	O
with	O
sporadic	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
for	O
the	O
first	O
5	O
years	O
and	O
every	O
2	O
years	O
thereafter	O
[	O
23	O
]	O
,	O
HNPCC	O
patients	O
with	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
.	O

Considering	O
the	O
increased	O
risk	O
of	O
extracolonic	O
manifestations	O
,	O
hereditary	O
colorectal	O
cancer	O
patients	O
were	O
also	O
submitted	O
to	O
periodical	O
instrumental	O
examinations	O
tailored	O
to	O
the	O
different	O
spectrum	O
of	O
the	O
disease	O
[	O
4,27	O
]	O
.	O

The	O
index	O
date	O
for	O
survival	O
calculation	O
was	O
defined	O
as	O
the	O
date	O
of	O
treatment	O
for	O
the	O
first	O
colorectal	O
cancer	O
.	O

Clinical	O
follow	O
-	O
up	O
procedures	O
provided	O
information	O
on	O
the	O
subject	O
's	O
status	O
.	O

Statistical	O
analysis	O
Survival	O
curves	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
stratified	O
according	O
to	O
various	O
clinical	O
and	O
pathological	O
variables	O
.	O

Differences	O
were	O
tested	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
regression	O
analysis	O
.	O

The	O
multivariate	O
analysis	O
of	O
the	O
HNPCC	O
versus	O
CRC	O
groups	O
,	O
Dukes	O
'	O
stage	O
,	O
tumor	O
site	O
showed	O
that	O
all	O
these	O
parameters	O
independently	O
affected	O
disease	O
-	O
specific	O
survival	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
<	O
0.0001	O
and	O
p	O
=	O
0.03	O
respectively	O
)	O
.	O

Out	O
of	O
40	O
HNPCC	O
patients	O
,	O
15	O
were	O
investigated	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
;	O
all	O
resulting	O
positive	O
.	O

Furthermore	O
,	O
the	O
HNPCC	O
patients	O
with	O
MSI	O
(	O
15	O
/	O
40	O
)	O
had	O
a	O
survival	O
of	O
100	O
%	O
.	O

Statistical	O
analysis	O
Mutation	O
rates	O
of	O
cell	O
lines	O
were	O
compared	O
by	O
T	O
-	O
test	O
or	O
one	O
-	O
way	O
ANOVA	O
.	O

